WO2024091586A1 - Radionuclide brachytherapy source systems for ocular radiotherapy - Google Patents
Radionuclide brachytherapy source systems for ocular radiotherapy Download PDFInfo
- Publication number
- WO2024091586A1 WO2024091586A1 PCT/US2023/035967 US2023035967W WO2024091586A1 WO 2024091586 A1 WO2024091586 A1 WO 2024091586A1 US 2023035967 W US2023035967 W US 2023035967W WO 2024091586 A1 WO2024091586 A1 WO 2024091586A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- preferred embodiments
- rbs
- radiation
- target
- macular edema
- Prior art date
Links
- 238000002725 brachytherapy Methods 0.000 title claims abstract description 45
- 238000001959 radiotherapy Methods 0.000 title abstract description 17
- 230000005855 radiation Effects 0.000 claims abstract description 117
- 208000001344 Macular Edema Diseases 0.000 claims abstract description 65
- 206010025415 Macular oedema Diseases 0.000 claims abstract description 44
- 201000010230 macular retinal edema Diseases 0.000 claims abstract description 44
- 206010012689 Diabetic retinopathy Diseases 0.000 claims abstract description 33
- 208000004644 retinal vein occlusion Diseases 0.000 claims abstract description 31
- 206010058202 Cystoid macular oedema Diseases 0.000 claims abstract description 21
- 201000010206 cystoid macular edema Diseases 0.000 claims abstract description 21
- 201000005667 central retinal vein occlusion Diseases 0.000 claims abstract description 18
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims abstract description 16
- 201000011190 diabetic macular edema Diseases 0.000 claims abstract description 16
- 238000011287 therapeutic dose Methods 0.000 claims description 162
- 238000000034 method Methods 0.000 claims description 83
- 238000011282 treatment Methods 0.000 claims description 61
- 230000001965 increasing effect Effects 0.000 claims description 32
- 210000001760 tenon capsule Anatomy 0.000 claims description 20
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims description 11
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims description 11
- 230000001678 irradiating effect Effects 0.000 claims description 11
- 102000008186 Collagen Human genes 0.000 claims description 10
- 108010035532 Collagen Proteins 0.000 claims description 10
- 229920001436 collagen Polymers 0.000 claims description 10
- 208000035719 Maculopathy Diseases 0.000 claims description 9
- 208000002780 macular degeneration Diseases 0.000 claims description 9
- 230000002285 radioactive effect Effects 0.000 claims description 9
- 206010068886 Radiation neuropathy Diseases 0.000 claims description 8
- 206010064714 Radiation retinopathy Diseases 0.000 claims description 8
- 230000008021 deposition Effects 0.000 claims description 8
- 230000001225 therapeutic effect Effects 0.000 claims description 8
- 230000005865 ionizing radiation Effects 0.000 claims description 6
- 208000002177 Cataract Diseases 0.000 claims description 4
- 230000008728 vascular permeability Effects 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 13
- 230000003247 decreasing effect Effects 0.000 abstract description 10
- 230000002411 adverse Effects 0.000 abstract description 9
- 230000008901 benefit Effects 0.000 abstract description 7
- 201000001718 Roberts syndrome Diseases 0.000 abstract 1
- 208000012474 Roberts-SC phocomelia syndrome Diseases 0.000 abstract 1
- 238000005001 rutherford backscattering spectroscopy Methods 0.000 abstract 1
- 210000003161 choroid Anatomy 0.000 description 81
- 208000003569 Central serous chorioretinopathy Diseases 0.000 description 70
- 238000013461 design Methods 0.000 description 30
- 210000001525 retina Anatomy 0.000 description 27
- 230000006378 damage Effects 0.000 description 19
- 239000012530 fluid Substances 0.000 description 19
- 210000003786 sclera Anatomy 0.000 description 19
- 238000002399 angioplasty Methods 0.000 description 17
- 230000000649 photocoagulation Effects 0.000 description 17
- 230000007423 decrease Effects 0.000 description 16
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 16
- 238000002428 photodynamic therapy Methods 0.000 description 15
- 230000002207 retinal effect Effects 0.000 description 15
- 210000004204 blood vessel Anatomy 0.000 description 13
- 230000001684 chronic effect Effects 0.000 description 12
- 230000035699 permeability Effects 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 238000009825 accumulation Methods 0.000 description 11
- 239000003246 corticosteroid Substances 0.000 description 11
- 230000007246 mechanism Effects 0.000 description 11
- 230000008069 intimal proliferation Effects 0.000 description 9
- 238000012014 optical coherence tomography Methods 0.000 description 9
- 201000004569 Blindness Diseases 0.000 description 8
- 206010025421 Macule Diseases 0.000 description 8
- 230000004393 visual impairment Effects 0.000 description 8
- 206010038848 Retinal detachment Diseases 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 206010012601 diabetes mellitus Diseases 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000002062 proliferating effect Effects 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 208000033379 Chorioretinopathy Diseases 0.000 description 6
- 206010029113 Neovascularisation Diseases 0.000 description 6
- 210000001367 artery Anatomy 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 6
- 229960001334 corticosteroids Drugs 0.000 description 6
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 6
- 206010020718 hyperplasia Diseases 0.000 description 6
- 238000003384 imaging method Methods 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 5
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 5
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 208000037803 restenosis Diseases 0.000 description 5
- 208000029257 vision disease Diseases 0.000 description 5
- 206010037756 Radiation cataract Diseases 0.000 description 4
- CIOAGBVUUVVLOB-NJFSPNSNSA-N Strontium-90 Chemical compound [90Sr] CIOAGBVUUVVLOB-NJFSPNSNSA-N 0.000 description 4
- 230000003511 endothelial effect Effects 0.000 description 4
- 230000004438 eyesight Effects 0.000 description 4
- 230000002641 glycemic effect Effects 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 210000002301 subretinal fluid Anatomy 0.000 description 4
- ZQFGRJWRSLZCSQ-ZSFNYQMMSA-N verteporfin Chemical compound C=1C([C@@]2([C@H](C(=O)OC)C(=CC=C22)C(=O)OC)C)=NC2=CC(C(=C2C=C)C)=NC2=CC(C(=C2CCC(O)=O)C)=NC2=CC2=NC=1C(C)=C2CCC(=O)OC ZQFGRJWRSLZCSQ-ZSFNYQMMSA-N 0.000 description 4
- 229960003895 verteporfin Drugs 0.000 description 4
- 206010003694 Atrophy Diseases 0.000 description 3
- 208000010412 Glaucoma Diseases 0.000 description 3
- 206010063341 Metamorphopsia Diseases 0.000 description 3
- 208000034698 Vitreous haemorrhage Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000037444 atrophy Effects 0.000 description 3
- 210000001775 bruch membrane Anatomy 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000008497 endothelial barrier function Effects 0.000 description 3
- 229960000890 hydrocortisone Drugs 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 230000001991 pathophysiological effect Effects 0.000 description 3
- 208000032253 retinal ischemia Diseases 0.000 description 3
- 230000004268 retinal thickening Effects 0.000 description 3
- 210000001210 retinal vessel Anatomy 0.000 description 3
- 230000008719 thickening Effects 0.000 description 3
- 210000005166 vasculature Anatomy 0.000 description 3
- 108091007504 ADAM10 Proteins 0.000 description 2
- 206010002329 Aneurysm Diseases 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102100039673 Disintegrin and metalloproteinase domain-containing protein 10 Human genes 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 206010058558 Hypoperfusion Diseases 0.000 description 2
- 208000009857 Microaneurysm Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 102000008790 VE-cadherin Human genes 0.000 description 2
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 2
- 206010053648 Vascular occlusion Diseases 0.000 description 2
- 206010047571 Visual impairment Diseases 0.000 description 2
- 208000000208 Wet Macular Degeneration Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 210000002469 basement membrane Anatomy 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004155 blood-retinal barrier Anatomy 0.000 description 2
- 230000004378 blood-retinal barrier Effects 0.000 description 2
- 108010018828 cadherin 5 Proteins 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 229960001208 eplerenone Drugs 0.000 description 2
- JUKPWJGBANNWMW-VWBFHTRKSA-N eplerenone Chemical compound C([C@@H]1[C@]2(C)C[C@H]3O[C@]33[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)C(=O)OC)C[C@@]21CCC(=O)O1 JUKPWJGBANNWMW-VWBFHTRKSA-N 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 238000009093 first-line therapy Methods 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 230000002706 hydrostatic effect Effects 0.000 description 2
- 230000004305 hyperopia Effects 0.000 description 2
- 201000006318 hyperopia Diseases 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 210000003093 intracellular space Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000007310 pathophysiology Effects 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000005086 pumping Methods 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000004264 retinal detachment Effects 0.000 description 2
- 210000001957 retinal vein Anatomy 0.000 description 2
- 238000009094 second-line therapy Methods 0.000 description 2
- 210000004911 serous fluid Anatomy 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 208000021331 vascular occlusion disease Diseases 0.000 description 2
- 230000004304 visual acuity Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
- 102000004888 Aquaporin 1 Human genes 0.000 description 1
- 108090001004 Aquaporin 1 Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241001631457 Cannula Species 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 208000014311 Cushing syndrome Diseases 0.000 description 1
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 description 1
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 206010067557 Dysmetropsia Diseases 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102100038591 Endothelial cell-selective adhesion molecule Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101000882622 Homo sapiens Endothelial cell-selective adhesion molecule Proteins 0.000 description 1
- 101000622304 Homo sapiens Vascular cell adhesion protein 1 Proteins 0.000 description 1
- 206010020675 Hypermetropia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 102000003979 Mineralocorticoid Receptors Human genes 0.000 description 1
- 108090000375 Mineralocorticoid Receptors Proteins 0.000 description 1
- 229940122522 Mineralocorticoid antagonist Drugs 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010061323 Optic neuropathy Diseases 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 108010069381 Platelet Endothelial Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 102000037602 Platelet Endothelial Cell Adhesion Molecule-1 Human genes 0.000 description 1
- 229940123934 Reductase inhibitor Drugs 0.000 description 1
- 208000037111 Retinal Hemorrhage Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038862 Retinal exudates Diseases 0.000 description 1
- 208000032398 Retinal pigment epitheliopathy Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 206010039729 Scotoma Diseases 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 208000032594 Vascular Remodeling Diseases 0.000 description 1
- 101710160666 Vascular cell adhesion protein 1 Proteins 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 239000000674 adrenergic antagonist Substances 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 description 1
- 239000003418 antiprogestin Substances 0.000 description 1
- 229940042786 antitubercular antibiotic Drugs 0.000 description 1
- 239000003231 antitubercular antibiotic Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 230000005255 beta decay Effects 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000002302 brachial artery Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000004456 color vision Effects 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000005782 double-strand break Effects 0.000 description 1
- 230000000235 effect on cancer Effects 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- 230000023143 endothelial cell-cell adhesion Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
- 229960002297 fenofibrate Drugs 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
- 229960004039 finasteride Drugs 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 208000018875 hypoxemia Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000013152 interventional procedure Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000018769 loss of vision Diseases 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960002237 metoprolol Drugs 0.000 description 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 1
- 229960003248 mifepristone Drugs 0.000 description 1
- 239000002395 mineralocorticoid Substances 0.000 description 1
- 239000002394 mineralocorticoid antagonist Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 201000005111 ocular hyperemia Diseases 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 208000020911 optic nerve disease Diseases 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000004796 pathophysiological change Effects 0.000 description 1
- 230000035778 pathophysiological process Effects 0.000 description 1
- 210000003668 pericyte Anatomy 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 108091008695 photoreceptors Proteins 0.000 description 1
- 230000036211 photosensitivity Effects 0.000 description 1
- 239000003504 photosensitizing agent Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940037129 plain mineralocorticoids for systemic use Drugs 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 230000003623 progesteronic effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000011555 rabbit model Methods 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000004232 retinal microvasculature Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 210000001578 tight junction Anatomy 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000028973 vesicle-mediated transport Effects 0.000 description 1
- 210000001235 zona fasciculata Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/00727—Apparatus for retinal reattachment
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09G—POLISHING COMPOSITIONS; SKI WAXES
- C09G1/00—Polishing compositions
- C09G1/02—Polishing compositions containing abrasives or grinding agents
Definitions
- This invention relates to the field of radiotherapy and more specifically to the subfield of brachytherapy, and to radionuclide brachytherapy sources (RBS) used to treat conditions of the eye, such as but not limited to diabetic retinopathy (DR) , diabetic macular edema (DME) , cystoid macular edema (CME) , macular edema (ME) secondary to central retinal vein occlusion (CRVO) , and ME secondary to branch retinal vein occlusion (BRVO) .
- DR diabetic retinopathy
- DME diabetic macular edema
- CME cystoid macular edema
- ME macular edema
- CRVO central retinal vein occlusion
- BRVO branch retinal vein occlusion
- CSCR Central Serous Chorioretinopathy
- CSCR Central Serous Chorioretinopathy
- CSCR typically causes blurred or distorted vision, e.g. , metamorphopsia . Patients may also report micropsia (objects appearing smaller than they really are) and/or color vision disturbances.
- Temporary hyperopia farsightedness
- CSCR may also cause a blurred or gray spot in the central visual field, which commonly occurs when the retina is detached. Reduced visual acuity may resolve upon resolution of CSCR, or may persist after the fluid accumulation that is associated with CSCR has dispersed and CSCR has resolved.
- CSCR is generally regarded as being of unknown cause, and mostly affects white males aged 20-50 years of age. It is believed that CSCR is associated with exogenous corticosteroid use. Further, CSCR is also believed to be associated with psychological stress, which in turn is associated with increased endogenous cortisol levels. Furthermore, other conditions associated with increased endogenous cortisol production, for example, Cushing syndrome and pregnancy, are also associated with an increased risk of developing CSCR. Cortisol is an endogenous glucocorticoid corticosteroid produced by the adrenal cortex, more specifically the zona fasciculata. Thus, it is believed that there is a general association between increased corticosteroid levels, whether from exogenous or endogenous sources, and the development of CSCR.
- CSCR is characterized by an accumulation of fluid under the retina.
- fluid has the propensity to accumulate under the macula, an oval area surrounding the fovea, a small depression in the retina where retinal cones are particularly concentrated and where visual acuity is highest.
- the source of this fluid is typically hyperpermeable large vessels of the choroid, e.g. , large choroidal vessels.
- Serous fluid leaked from the choroid, accumulates under the retina, causing small and localized detachments of the neurosensory layer of the macula (a part of the retina) , with or without concomitant detachment of the retinal pigment epithelium (RPE) , e.g., with or without pigment epithelial detachment (PED) .
- RPE retinal pigment epithelium
- PED pigment epithelial detachment
- the choroid is the vascular layer of the eye, sitting between the retina (deep to the choroid) and the sclera (superficial to the choroid) .
- the choroid provides blood flow to much of the retina.
- the choroid is divided into four layers. From most superficial (farthest from the retina) to deepest (closest to the retina) , the layers are: Haller' s layer, Sattler' s layer, choriocapillaris, and Bruch' s membrane.
- Haller's layer is the outermost (most superficial) layer of the choroid, and contains the largest choroidal vessels. Sattler' s layer is deep to Haller' s layer, and contains medium-sized choroidal vessels.
- the choriocapillaris is deep to Sattler' s layer, and contains capillaries, e.g. , small vessels.
- Bruch' s membrane is the innermost (e.g. , deepest) layer of the choroid, contains small vessels, and contains the basement membrane of both the choriocapillaris (on its most outermost side) and the basement membrane of the retinal pigment epithelium (on its innermost side) .
- the primary disease process involved in CSCR is serous fluid leakage from large choroidal vessels, subsequent fluid accumulation under the macula, and resultant detachment of the neurosensory layer of the macula, with or without PED.
- the pathophysiology of CSCR is multifactorial.
- Choroidal inflammation leads to vessel stasis, hyperpermeability, and thickening of the choroid.
- characteristic intermediate elements of CSCR' s pathology are choroidal hyperpermeability and choroidal thickening.
- increased tissue pressure on the RPE results, which results in damage to the RPE and may cause PED. Damage to the RPE decreases its effectiveness as a barrier, and choroidal fluid can thus cross the RPE, resulting in detachment of the neurosensory layer.
- CSCR may result in the loss of polarity of the RPE.
- the RPE pumps fluid from the subretinal space into the choroid, keeping the retina in a relatively "dry" state.
- the RPE may reverse its pumping direction, pumping fluid from the choroid into the subretinal space. This may lead to subretinal fluid accumulation.
- choriocapillaris attenuation and hypoperfusion may result in elevated hydrostatic pressure and a resultant decrease in reabsorption performed by capillaries of the choriocapillaris. Again, this may contribute to subretinal fluid accumulation.
- CSCR resolves spontaneously in the majority of cases and normal vision is regained, however recurrent retinal detachment is common. Because the condition is generally self-resolving, most clinicians will observe the patient for three to six months while attempting to correct any predisposing factors (e.g., tapering and stopping exogenous steroids, reducing the patient' s stress, etc.) . If CSCR and associated symptoms persist for over three to six months, or if detachment reoccurs, CSCR may be classified as chronic CSCR. Chronic CSCR leads to permanent pathophysiological changes, e.g. , foveal atrophy and changes to the retinal pigment epithelium. Chronic cases, if untreated, lead to permanent vision loss. Therefore, treatment is indicated for chronic CSCR. The most widely-utilized prior art treatments with the greatest level of evidence are laser photocoagulation and photodynamic therapy (PDT) .
- PDT photodynamic therapy
- Laser photocoagulation uses a laser to emit light which is absorbed by the targeted tissue, raising the tissue' s temperature and causing subsequent denaturation of proteins. Leakage sites on the retinal pigment epithelium are visualized with angiography and indicated by sites of hyperfluorescence, and these sites are then targeted with the laser. The leakage point is thus sealed, which decreases the time until subretinal fluid is cleared.
- laser photocoagulation suffers from several shortcomings. Laser photocoagulation is not an option if retinal pigment epithelial detachments involve the fovea, as the laser may cause permanent vision loss if used on the fovea. Laser photocoagulation is not proven to reduce the chance of recurrence of CSCR.
- Laser photocoagulation results in destruction of surrounding healthy retinal tissue, and may thus lead to the development of scotomas (spots of total or partial blindness in an otherwise normal field of vision) .
- Laser photocoagulation may also lead to choroidal neovascularization and further vision loss, particularly if the Bruch' s membrane is damaged by the laser. The potential development of these adverse effects thus requires frequent ophthalmological follow up for patients who have undergone laser photocoagulation.
- Laser photocoagulation is now considered an outdated treatment methodology by many clinicians .
- Photodynamic therapy is another option to treat CSCR.
- PDT is especially preferred over laser photocoagulation in cases where there is a leak on or near the fovea, where there are multiple leaks, and where there is diffuse decompensation of the retinal pigment epithelium.
- Verteporfin a photosensitizer, is injected intravenously. Verteporfin reaches the eye via the bloodstream and is activated by light with a wavelength of 689 nm, producing short-lived reactive oxygen species and causing local damage and blockage of blood vessels in areas targeted by the light source.
- PDT thus seals sources of choroidal leaks, and results in choroidal vascular remodeling and choroidal hypoperfusion, further reducing choroidal hyperpermeability.
- PDT is generally considered to be more effective and safer than laser photocoagulation.
- Low fluence or half-fluence PDT, or low-dose or half-dose PDT (using a lower or half dose of verteporfin) has been found to be equally effective as standard fluence or standard dose PDT, with a more favorable adverse effect profile.
- PDT is still associated with shortcomings, such as a need to minimize UV exposure following treatment and photosensitivity.
- Standard fluence PDT has also been associated with significant damage to the choriocapillaris , although reduced-fluence PDT has decreased the prevalence of this complication .
- Anti-VEGF therapy including intravitreal injections with anti-VEGF agents like bevacizumab, has shown a lack of benefit in CSCR.
- the rationale for the use of anti-VEGF agents in CSCR has been widely questioned, because there is no known overexpression of VEGF in CSCR and CSCR is generally not associated with angiogenesis or neovascularization.
- the pharmacological rationale for anti-VEGF use in CSCR is generally considered lacking.
- Conflicting evidence or a general lack of demonstrated efficacy has thus confined most treatment of CSCR to either laser photocoagulation (a more limited treatment, considered outdated by some clinicians) or PDT (which is generally preferred over laser photocoagulation) .
- DM Diabetes mellitus
- DME diabetic macular edema
- DR diabetic retinopathy
- Non-proliferat ive DR typically presents late in the first decade or early in the second decade of DR and is characterized by retinal vascular microaneurysms, blot hemorrhages, and cotton-wool spots.
- Nonproliferative DR may be characterized by changes in venous vessel caliber, intraretinal microvascular abnormalities, and more numerous microaneurysms and hemorrhages.
- Non-proliferat ive DR' s pathophysiology is defined by loss of retinal pericytes, increased retinal vascular permeability, alterations to retinal blood flow, and abnormal retinal microvasculature, all of which may lead to retinal ischemia.
- Proliferative DR features neovascularization in response to retinal hypoxemia. Newly formed vessels appear near the optic nerve and/or macula and rupture easily, in turns causing vitreous hemorrhage, fibrosis, and retinal detachment.
- Non-proliferat ive DR does not always evolve into proliferative DR, however the greater the severity of nonproliferative DR, the greater the likelihood of it evolving into proliferative DR within five years.
- DME diabetic macular edema
- Pharmacological treatments for DR include fenofibrate, which slows the progression of DR, and anti-VEGF therapy delivered via ocular injection, which may help preserve vision.
- Interventional procedures for DR include laser photocoagulation, which may also help preserve vision.
- Cystoid macular edema is a retinal thickening of the macula due to disruption of the normal function of the blood- retinal barrier, leading to leakage of perifoveal retinal capillaries and subsequent accumulation of fluid with the intracellular spaces of the retina. Loss of vision occurs via retinal thickening and fluid collection that distorts the photoreceptors.
- a balance between osmotic pressure, hydrostatic force, capillary permeability, and tissue compliance maintains the normal retinal environment.
- An imbalance between capillary filtration rate and fluid removal from the retinal extracellular space may result in fluid accumulation in the cystoid spaces in the inner layers of the retina, particularly the outer plexiform layer (OPL) .
- Vit reomacular traction can exert fractional force on retinal cells, in turn causing release of inflammatory mediators, e.g., basic fibroblastic growth factor (bFGF) , vascular endothelial growth factor (VEGF) , and platelet derived growth factor (PDGF) .
- bFGF basic fibroblastic growth factor
- VEGF vascular endothelial growth factor
- PDGF platelet derived growth factor
- NSAIDs to decrease prostaglandin production, as E2-prostaglandins are implicated in causing disruption of tight junctions in retinal capillaries
- corticosteroids including corticosteroid-based intravitreal implants
- carbonic anhydrase inhibitors help move fluid out of the retinal intracellular spaces
- Surgical treatments in the prior art have included pars plana vitrectomy (PPV) , which has uneven efficacy depending on etiology (particularly in CME with significant nontract ional components) , and has the downside of being invasive.
- PSV pars plana vitrectomy
- Other less-frequent ly utilized surgical treatments include laser photocoagulation, cryopexy, and various glaucoma-related procedures.
- CRVO Central Retinal Vein Occlusion
- ME Central Retinal Vein Occlusion
- CRVO is a form of retinal vein occlusion. It is a vascular occlusion of the central retinal vein, which in turn results in largely the same pathophysiological features of CME (listed above) , namely macular edema, retinal ischemia, and neovascular complications including glaucoma, vitreous hemorrhage, and retinal traction .
- Prior art treatments of ME secondary to CRVO have included anti-VEGF and corticosteroids (injections or implants) to manage neovascularization and macular edema, respectively.
- Anti- VEGF injections are first-line therapy, and corticosteroids are generally second-line therapy.
- Panretinal photocoagulation has been used to treat neovascularization of the iris associated with ME secondary to CRVO .
- Branch Retinal Vein Occlusion may also cause ME.
- BRVO is a form of retinal vein occlusion. It is a vascular occlusion of any branch of the central retinal vein, which in turn results in the largely the same pathophysiological features of CME (listed above) , namely macular edema, retinal ischemia, and neovascular complications including glaucoma, vitreous hemorrhage, and retinal traction.
- Prior art treatments of ME secondary to BRVO have included anti-VEGF and corticosteroids (injections or implants) to manage neovascularization and macular edema, respectively.
- Anti- VEGF injections are first-line therapy, and corticosteroids are generally second-line therapy.
- Grid laser photocoagulation may be used to manage macular edema secondary to BRVO.
- Preferred embodiments of the present invention provide devices and compositions that allow for irradiating a choroid target in an eye, as specified in the independent claims. Preferred embodiments of the invention are given in the dependent claims. Preferred embodiments of the present invention can be freely combined with each other if they are not mutually exclusive.
- the present invention may be used to treat chronic serous chorioretinopathy (CSCR) .
- the present invention features a radionuclide brachytherapy source (RBS) for use in a method of irradiating a target of an eye, wherein said RBS is present in a cannula of a delivery device, the method comprising inserting said cannula into a potential space under a Tenon' s capsule of the eye, whereby the RBS is positioned over a choroid target at the back of the eye, wherein a therapeutic dose of radiation is delivered to the choroid target, wherein a radioactive therapeutic portion of the RBS is consumed during the method.
- RBS radionuclide brachytherapy source
- the therapeutic doses are generally selected such that intimal proliferation of large choroidal vessels is increased while damages to vessels of the choriocapillaris and other radiosensitive structures of the eye, such as the lens, are minimized .
- the therapeutic dose is from 6 to 18 Gy. In some preferred embodiments the therapeutic dose is 6-8 Gy. In some preferred embodiments the therapeutic dose is 6-10 Gy. In some preferred embodiments the therapeutic dose is 6-12 Gy. In some preferred embodiments the therapeutic dose is 6- 16 Gy. In some preferred embodiments the therapeutic dose is 8-10
- the therapeutic dose is 8-12 Gy.
- the therapeutic dose is 8-16 Gy. In some preferred embodiments the therapeutic dose is 8-18 Gy. In some preferred embodiments the therapeutic dose is 10-12 Gy. In some preferred embodiments the therapeutic dose is 10-14 Gy. In some preferred embodiments the therapeutic dose is 10-18 Gy. In some preferred embodiments the therapeutic dose is 12-16 Gy. In some preferred embodiments the therapeutic dose is 12-18 Gy. In some preferred embodiments the therapeutic dose is 14-18 Gy.
- the therapeutic dose is delivered to a particular depth or range of depths, e.g., as measured from the interface of the sclera and the delivery device.
- the therapeutic dose delivered to a depth from 0.5 mm to 2 mm is from 6-18 Gy.
- the therapeutic dose delivered to a depth from 0.5 mm to 2 mm is from 6-16 Gy.
- the therapeutic dose delivered to a depth from 0.5 mm to 2 mm is from 6-14 Gy.
- the therapeutic dose delivered to a depth from 0.5 mm to 2 mm is from 6-12 Gy.
- the therapeutic dose delivered to a depth from 0.5 mm to 2 mm is from 8-18 Gy.
- the therapeutic dose delivered to a depth from 0.5 mm to 2 mm is from 8-16 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 0.5 mm to 2 mm is from 8-14 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 0.5 mm to 2 mm is from 8-12 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 0.75 mm to 1.75 mm is from 6-18 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 0.75 mm to 1.75 mm is from 6-16 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 0.75 mm to 1.75 mm is from 6-14 Gy.
- the therapeutic dose delivered to a depth from 0.75 mm to 1.75 mm is from 6-12 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 0.75 mm to 1.75 mm is from 8-18 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 0.75 mm to 1.75 mm is from 8-16 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 0.75 mm to 1.75 mm is from 8-14 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 0.75 mm to 1.75 mm is from 8-12 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 1 mm to 1.5 mm is from 6-18 Gy.
- the therapeutic dose delivered to a depth from 1 mm to 1.5 mm is from 6-16 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 1 mm to 1.5 mm is from 6-14 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 1 mm to 1.5 mm is from 6-12 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 1 mm to 1.5 mm is from 8-18 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 1 mm to 1.5 mm is from 8-16 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 1 mm to 1.5 mm is from 8-14 Gy.
- the therapeutic dose delivered to a depth from 1 mm to 1.5 mm is from 8-12 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 0.5 mm to 1.25 mm is from 6-18 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 0.5 mm to 1.25 mm is from 6-16 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 0.5 mm to 1.25 mm is from 6-14 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 0.5 mm to 1.25 mm is from 6-12 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 0.5 mm to 1.25 mm is from 8-18 Gy.
- the therapeutic dose delivered to a depth from 0.5 mm to 1.25 mm is from 8-16 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 0.5 mm to 1.25 mm is from 8-14 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 0.5 mm to 1.25 mm is from 8-12 Gy.
- the therapeutic dose is calculated based on the thickness of the choroid target. In some preferred embodiments, the thickness of the choroid target is measured using imaging.
- the retina is exposed to less than 8 Gy. In some preferred embodiments, a choriocapillaris is exposed to less than 10 Gy. In some preferred embodiments, an interface of large choroidal vessels and a choriocapillaris is exposed to less than 12 Gy. In some preferred embodiments, the retina is exposed to less radiation than the choroid target. In some preferred embodiments, a choriocapillaris is exposed to less radiation than the choroid target.
- the therapeutic dose is fractionated over multiple sessions.
- the therapeutic dose may be fractionated over at least two sessions.
- the dose is delivered to the choroid target in a period of time, e.g. , a dwell time.
- the dwell time is from 5 seconds to 10 minutes.
- the dwell time is from 5 seconds to 15 second.
- the dwell time is from 5 seconds to 30 seconds.
- the dwell time is from 5 seconds to 45 seconds.
- the dwell time is from 5 seconds to 1 minute.
- the dwell time is from 5 seconds to 2 minutes.
- the dwell time is from 15 seconds to 30 seconds. In some preferred embodiments, the dwell time is from 15 seconds to 1 minute. In some preferred embodiments, the dwell time is from 15 seconds to 90 seconds. In some preferred embodiments, the dwell time is from 15 seconds to 2 minutes. In some preferred embodiments, the dwell time is from 30 seconds to 1 minute. In some preferred embodiments, the dwell time is from 1 minute to 90 seconds. In some preferred embodiments, the dwell time is from 1 minute to 2 minutes. In some preferred embodiments, the dwell time is from 90 seconds to 2 minutes. In some preferred embodiments, the dwell time is from 2 to 4 minutes. In some preferred embodiments, the dwell time is from 4 to 6 minutes. In some preferred embodiments, the dwell time is from 6 to 8 minutes. In some preferred embodiments, the dwell time is from 8 to 10 minutes. In some preferred embodiments the dwell time is from 5 to 10 minutes. In some preferred embodiments, the dwell time is greater than 10 minutes.
- the RBS delivers radiation to an irradiated area, e.g., having a diameter.
- the diameter of the irradiated area is up to 6 millimeters. In some preferred embodiments, the diameter of the irradiated area is up to 8 millimeters. In some preferred embodiments, the diameter of the irradiated area is up to 10 millimeters. In some preferred embodiments, the diameter of the irradiated area is up to 12 millimeters. In some preferred embodiments, the diameter of the irradiated area is 3-5 millimeters. The present invention is not limited to the aforementioned diameters.
- the RBS is a source of ionizing radiation. In some preferred embodiments, the RBS is a source of particle radiation. In some preferred embodiments, the RBS is a source of beta radiation. In some preferred embodiments, the RBS is a source of X-ray radiation. In some preferred embodiments, the RBS is a source of multiple types of radiation.
- the RBS is contained within a cannula.
- the cannula is part of a delivery device.
- the delivery device comprises: a cannula comprising a curved distal portion adapted for placement around a portion of a globe of an eye; a curved proximal portion, the curved distal portion and the curved proximal portions being connected with each other at an inflection point where the direction of the curvature changes sign; and a straight proximal portion.
- the distal portion has a radius of curvature between about 9 mm to 15 mm and an arc length between about 25 mm to 35 mm; and the proximal portion has a radius of curvature between about an inner cross-sectional radius of the cannula and about 1 meter; and an angle 0i between a line [ 3 tangent to the distal portion and to the curved proximal portion at the inflection point and the straight proximal portion is between greater than about 0 degrees to about 180 degrees.
- the present invention is not limited to the aforementioned delivery device or cannula.
- the present invention features a method of reducing hyperpermeability of large choroidal vessels in an eye of a patient in need thereof with central serous chorioretinopathy.
- the method comprises inserting a cannula into a potential space under a Tenon' s capsule of the eye of the patient, the cannula having a radionuclide brachytherapy source (RBS) at a treatment position, whereby the RBS is positioned over a choroid target, and wherein a therapeutic dose of radiation is delivered to the choroid target.
- RBS radionuclide brachytherapy source
- the present invention features a method of increasing collagen deposition associated with large choroidal vessels in an eye of a patient in need thereof with central serous chorioretinopathy.
- the method comprises inserting a cannula into a potential space under a Tenon' s capsule of the eye of the patient, the cannula having a radionuclide brachytherapy source (RBS) at a treatment position, whereby the RBS is positioned over a choroid target, and wherein a therapeutic dose of radiation is delivered to the choroid target.
- RBS radionuclide brachytherapy source
- the method comprises inserting a cannula into a potential space under a Tenon' s capsule of an eye of the patient, the cannula having a radionuclide brachytherapy source (RBS) at a treatment position, whereby the RBS is positioned over a choroid target, and wherein a therapeutic dose of radiation is delivered to the choroid target.
- RBS radionuclide brachytherapy source
- the therapeutic dose is from 6 to 18 Gy. In some preferred embodiments the therapeutic dose is 6-8 Gy. In some preferred embodiments the therapeutic dose is 6-10 Gy. In some preferred embodiments the therapeutic dose is 6-12 Gy. In some preferred embodiments the therapeutic dose is 6-16 Gy. In some preferred embodiments the therapeutic dose is 8-10 Gy. In some preferred embodiments the therapeutic dose is 8-12 Gy. In some preferred embodiments the therapeutic dose is 8-16 Gy. In some preferred embodiments the therapeutic dose is 8-18 Gy. In some preferred embodiments the therapeutic dose is 10-12 Gy. In some preferred embodiments the therapeutic dose is 10-14 Gy. In some preferred embodiments the therapeutic dose is 10-18 Gy. In some preferred embodiments the therapeutic dose is 12-16 Gy. In some preferred embodiments the therapeutic dose is 12-18 Gy. In some preferred embodiments the therapeutic dose : s 14-18 Gy.
- th « retina is exposed to less than 8 Gy.
- a choriocapillaris is exposed to less than 10 Gy.
- an interface of large choroidal vessels and a choriocapillaris is exposed to less than 12 Gy.
- a retina is exposed to less radiation than the choroid target.
- a choriocapillaris is exposed to less radiation than the choroid target .
- the therapeutic dose is fractionated over multiple sessions.
- the therapeutic dose may be fractionated over at least two sessions.
- the dose is delivered to the choroid target in a period of time, e.g. , a dwell time.
- the dwell time is from 5 seconds to 10 minutes.
- the dwell time is from 5 seconds to 15 second.
- the dwell time is from 5 seconds to 30 seconds.
- the dwell time is from 5 seconds to 45 seconds.
- the dwell time is from 5 seconds to 1 minute.
- the dwell time is from 5 seconds to 2 minutes.
- the dwell time is from 15 seconds to 30 seconds.
- the dwell time is from 15 seconds to 1 minute.
- the dwell time is from 15 seconds to 90 seconds.
- the dwell time is from 15 seconds to 2 minutes. In some preferred embodiments, the dwell time is from 30 seconds to 1 minute. In some preferred embodiments, the dwell time is from 1 minute to 90 seconds. In some preferred embodiments, the dwell time is from 1 minute to 2 minutes. In some preferred embodiments, the dwell time is from 90 seconds to 2 minutes. In some preferred embodiments, the dwell time is from 2 to 4 minutes. In some preferred embodiments, the dwell time is from 4 to 6 minutes. In some preferred embodiments, the dwell time is from 6 to 8 minutes. In some preferred embodiments, the dwell time is from 8 to 10 minutes. In some preferred embodiments the dwell time is from 5 to 10 minutes. In some preferred embodiments, the dwell time is greater than 10 minutes.
- the RBS delivers radiation to a treatment area, wherein a diameter of the treatment area is up to 8 millimeters.
- the RBS is a source of ionizing radiation.
- the RBS is a source of beta radiation.
- the RBS is a source of X-ray radiation.
- the RBS is a source of multiple types of radiation.
- the RBS is contained within a cannula.
- the cannula is part of a delivery device.
- the delivery device comprises: a cannula comprising a curved distal portion adapted for placement around a portion of a globe of an eye; a curved proximal portion, the curved distal portion and the curved proximal portions being connected with each other at an inflection point where the direction of the curvature changes sign; and a straight proximal portion.
- the distal portion has a radius of curvature between about 9 mm to 15 mm and an arc length between about 25 mm to 35 mm; and the proximal portion has a radius of curvature between about an inner cross-sectional radius of the cannula and about 1 meter; and an angle 01 between a line 13 tangent to the distal portion and to the curved proximal portion at the inflection point and the straight proximal portion is between greater than about 0 degrees to about 180 degrees.
- the present invention is not limited to the aforementioned delivery device or cannula.
- the dose delivered is such that radiation retinopathy is avoided. In some preferred embodiments, the dose delivered is such that radiation choroidopathy is avoided. In some preferred embodiments, the dose delivered is such that radiation maculopathy is avoided. In some preferred embodiments, the dose delivered is such that radiation neuropathy is avoided. In some preferred embodiments, the dose delivered is such that cataract is avoided. In some preferred embodiments, the dose delivered is such that choroidal neovascularization is avoided.
- One of the unique and inventive technical features of the present invention is the ability to provide a therapeutically effective dose to the choroid target while avoiding or minimizing damage to other structures of the eye, for example the retina and choriocapillaris .
- the technical feature of the present invention advantageously provides for treatment efficacy while avoiding or minimizing adverse effects of treatment, for example the development of radiation retinopathy, radiation choroidopathy, radiation maculopathy, radiation neuropathy, cataract, and/or choroidal neovascularization. None of the presently known prior references or work has the unique inventive technical feature of the present invention.
- the present invention represents an unexpected advancement in the field of brachytherapy. As will be described herein, prior uses of brachytherapy, and radiotherapy more generally, have taught away from the use of brachytherapy for the treatment of CSCR as implemented in the present invention.
- Radiotherapy and brachytherapy, as a subfield of radiotherapy
- the fact that the present invention decreases vascular permeability through the use of radiation is a surprising result.
- Radiation has for many decades been taught as increasing vascular permeability: "Research in the 1940' s and 50' s suggested that multiple mechanisms were responsible for increased endothelial barrier permeability following radiation exposure.” (Bouten et al. , (2021) Tissue Barriers in Disease, Injury and Regeneration (pp. 43-94) . Elsevier) .
- the prior art teaches away from using even low doses of radiation to decrease vascular permeability, since the prior art teaches that even low doses of radiation increase vascular permeability.
- the present invention surprisingly produces a reduction in vascular permeability via the use of low and well-controlled doses of radiation .
- VE-cadherin This has been correlated with decreased amounts of two junction proteins, one of which was VE-cadherin.
- VE-cadherin was cleaved by ADAM10 in a radiation dose-dependent manner, which appears to be mediated at least in part by intracellular calcium release. Inhibition of ADAMIO rescued radiation-induced permeability (Kabacik, S. et al. (2017) . Oncotarget, 8 (47) , 82049-82063) .
- Coronary brachytherapy is used in conjunction with coronary angioplasty, and operates on the principle that, in short, radiation delivered to a blood vessel will prevent thickening of the vessel' s wall.
- Atherosclerosis is the formation of fatty plaques in the lumen of arteries, which reduces the area of the lumen, inhibiting blood flow and oxygen delivery to tissues (Nath, R. , et al. (1999) , Med. Phys. , 26: 119-152) .
- Plaque formation eventually causes smooth muscle cell proliferation, accompanied by collagen and elastin proliferation.
- fibrous plaques begin to form which contain lipids, necrotic cells, and collagen. These lesions calcify, causing platelet aggregation, a reduction in blood flow, and formation of a thrombosis, which, particularly if located in the heart, may cause myocardial ischemia or myocardial infarction.
- angioplasty Percutaneous transluminal angioplasty
- the primary goal of angioplasty is to reestablish a stable lumen with a diameter similar to a normal, healthy artery.
- Angioplasty is a practice well-known in the art that can be accomplished using a variety of devices and techniques. Described herein in gross detail as an exemplary form of angioplasty is balloon angioplasty.
- a catheter on a guidewire is introduced into an artery (typically the femoral artery or brachial artery) , and advanced with the aid of imaging to the target artery, usually a coronary artery.
- the angioplasty device for example, a balloon angioplasty device
- the angioplasty device is then inserted and guided via the guidewire to the site of the target lesion to be treated.
- the angioplasty device e.g., a balloon angioplasty device
- Use of the device e.g. , inflation of the balloon is intended to increase the diameter of the artery and break up plaques in the target lesion.
- Intimal proliferation is the result of new tissue growth which proliferates to fill in fissures in the vessel wall produced by the stretching trauma of the angioplasty procedure. Often, this tissue proliferation may occur to the extent that the vessel is severely re-obstructed. Late contraction resembles wound contracture, and is sometimes referred to as remodeling. It essentially involves healed tissues becoming contracted such that the circumference of the vessel is smaller after the procedure than it was before the procedure.
- Intimal hyperplasia (the second mechanism of restenosis) is particularly problematic, with excessive neointimal hyperplasia causing clinically symptomatic restenosis in three to six months in roughly 40% of patients. (Nath, R., et al. (1999) )
- the present invention uses radiation to increase proliferation of certain cells in blood vessel walls, thereby decreasing the permeability of those vessels. This is in contrast to the prior art, which teaches that radiation, even at low doses, decreases cellular proliferation, including by decreasing proliferation of cells in vessel walls (e.g. , including by decreasing intimal hyperplasia) .
- the present invention utilizes radiation to increase cellular proliferation of cells in choroidal vessel walls, thus decreasing the permeability of these vessels.
- Choroidal vessels in a patient with chronic serous chorioretinopathy are thereby made less permeable, reducing the amount of fluid they leak.
- less fluid accumulates under the retina, which resolves the underlying pathophysiological cause of CSCR, thus treating CSCR by stopping the disease process which causes it.
- an advantage of the present invention over previous approaches is that the present invention is capable of increasing intimal proliferation of large choroidal vessels while simultaneously minimizing damage to smaller blood vessels, especially those of the choriocapillaris .
- Other approaches have shown to cause damage to smaller, more delicate vessels, perhaps most importantly those of the choriocapillaris .
- Attenuation of the choriocapillaris is often an inherent part of the pathophysiological process of CSCR. Therefore, while it is always desirable to avoid unnecessary damage to the choriocapillaris, doing so is especially important in CSCR, given that the choriocapillaris is often compromised by the disease state itself.
- the present invention resolves this issue by allowing for the delivery of radiotherapy to the eye such that intimal proliferation of large choroidal vessels is increased, thereby decreasing their permeability, while minimizing damage to the smaller vessels of the choriocapillaris or the retina. In some preferred embodiments, this is accomplished in part by the delivery of an appropriate dose.
- the therapeutic dose is from 6 to 18 Gy. As will be described herein, the present invention is not limited to 6 to 18 Gy. Without wishing to limit the present invention to any theory or mechanism, it is believed that the doses in these ranges are such that intimal proliferation of large choroidal vessels is increased while minimizing damages to vessels of the choriocapillaris and other radiosensitive structures of the eye, such as the lens.
- the present invention features the use of specialized delivery devices such as but not limited to those described in US Patent Application No: 10/836, 140; US Patent Application No: 12/350, 079; US Patent Application No: 12/497, 644; US Patent Application No: 13/111, 765; US Patent Application No: 13/111, 780; US Patent Application No: 13/742, 823; US Patent Application No: 13/872, 941; US Patent Application No: 13/953, 528; US Patent Application No: 14/011, 516; US Patent Application No: 14/486, 401; US Patent Application No: 14/687,784; US Patent Application No: 15/871, 756; US Patent Application No: 15/023, 196; US Patent Application No: 15/004, 538; US Patent Application No: 15/628, 952; US Patent Application No: 16/015, 892; US Patent Application No: 16/009, 646; U.S.
- the present invention may therefore minimize the risk associated with any one or more of the following adverse effects associated with radiotherapy: radiation retinopathy, radiation choroidopathy, radiation maculopathy, radiation neuropathy, cataract, and choroidal neovascularization. In some preferred embodiments the present invention may minimize the risk associated with other adverse effects associated with radiotherapy, especially those associated with delivery of excessive doses of radiation.
- FIG. 1 shows a depiction of exponential decline in radiation dose with depth from the device. Graph showing exponential decline of the dose of radiation with increasing depth from the device.
- FIG. 2 shows doses of radiation delivered at different depths from the scleral surface (device-sclera interface) .
- Dose Dn exp[- 0.846 (d- dn) ] , where the depth of interest is d.
- Dn is the dose at the depth dn which is the normalization depth (or treatment depth)
- FIG. 3 shows that in a normal eye, the dose of radiation delivered at the sclera-choroid interface is 12.4 Gy. The dose is 10 Gy at the interface of large choroidal vessels and medium vessels/ chor iocapillar is .
- FIG. 4 shows that in an eye with central serous chorioretinopathy (CSCR) , the dose of radiation delivered at the sclera-choroid interface would be less than 12.4 Gy, considering the increased scleral thickness in CSCR.
- the dose of radiation at the interface of large choroidal vessels and medium vessels/choriocapillaris will be 8 Gy because of the increased thickness of the large choroidal vessels layer.
- FIG. 5 shows an episcleral brachytherapy device introduced via sub-Tenon route to deliver radiation to a choroidal neovascular complex through the sclera.
- FIG. 6 shows a non-limiting example of a cannula/delivery device.
- FIG. 7A shows a non-limiting example of a cannula/delivery device.
- FIG. 7B shows a detailed view of the radius of curvature of a portion of a cannula.
- FIG. 7C shows a detailed view of the radius of curvature of a portion of a cannula.
- FIG. 7D shows a detailed view of the relationship between the straight portion of the cannula and the distal and proximal portions of a cannula.
- the present invention features radionuclide brachytherapy sources (RBS) for applying radiation to a target area, for example for treating chronic serous chorioretinopathy (CSCR) .
- RBS radionuclide brachytherapy sources
- CSCR chronic serous chorioretinopathy
- the present invention may be used to provide low dose radiation via episcleral brachytherapy in refractory cases of central serous chorioretinopathy (CSCR) .
- CSCR central serous chorioretinopathy
- CSCR The pathogenesis of CSCR involves dilatation and hyperpermeability of large choroidal vessels.
- Low dose radiation can induce intimal proliferation in large choroidal vessels and decrease their hyperpermeability.
- Concerns about the use of brachytherapy in CSCR include damage to the choriocapillaris or the retinal vessels. This can be addressed with the use of a specialized device through which a very precise and appropriate dose can be delivered. The dose of the radiation delivered decreases exponentially at a depth of approximately 0.5-1.5 mm from the device-sclera interface.
- CSCR Central serous chorioretinopathy
- RPE retinal pigment epithelium
- Choroidal features of CSCR are choriocapillaris attenuation and dilatation of large vessels of the choroid. Whether dilated large vessels of the choroid cause a mechanical compression of the choriocapillaris layer, or atrophy of the choriocapillaris is the primary event, is still debatable.
- the prime target of the present invention is the hyperpermeable choroidal vasculature.
- Concerns associated with plaque radiotherapy include platelet aggregates, development of choroidal neovascularization (CNV) , radiation maculopathy, optic neuropathy, and radiation chorioretinopathy.
- CNV choroidal neovascularization
- Radionuclide strontium-90 (90Sr) emits only high energy beta particles which have highest attenuation in biological tissues making it more suitable for ocular use.
- Yttrium-90 (90Y) is the daughter product of 90Sr after beta decay and emits more energetic beta particles.
- Stereotactic radiotherapy is another method of radiotherapy that provides stereotactic application of low energy X-ray to the CNV using three highly collimated beams that cross the inferior sclera to overlap at the macula. Unlike epimacular brachytherapy, this outpatient-based radiotherapy does not require vitrectomy and thus is a more practical method of radiotherapy.
- An aim of the present invention is to decrease the blood flow through the large choroidal vessels without obliteration of the choriocapillaris . The mechanism of action in this case would likely be due to the effect of radiation on the endothelial cells. The radiation dose can even be reduced further to attain the desired effect of producing intimal proliferation whereby the leakiness stops or is reduced.
- the lower radiation dose will cause deposition of collagen around the leaky vessels thus changing their permeability over a period of months.
- the dose of the radiation is an exponential function for depths from approximately 0.5 mm to 1.5 mm, where the depth is measured from the front face of the device (the device-sclera interface has a depth of zero) .
- Dose D n exp[- 0.846 (d-d n ) ] , where the depth of interest is d.
- D n is the dose at the depth d n which is the normalization depth (or treatment depth) .
- choroidal thickness at the macula is around 256 Im of which 2041m is occupied by the large vessels (Haller layer) and 521m by the choriocapillaris/Satt ler layer in normal eyes.
- total choroidal thickness is increased (394 pm) because of increased thickness of the large vessel layer (307 pm) .
- Scleral thickness at the posterior pole is around 1 mm.
- scleral thickness at the posterior pole has not been measured in eyes with CSCR, scleral thickness 6 mm posterior to the scleral spur, as measured on anterior segment optical coherence tomography, is thicker than in normal eyes and an increased scleral thickness has been implicated in the pathogenesis of CSCR.
- the typical human choroid is generally between 0.5 mm to 1.5 mm deep in the structure of the eye, as measured from the posterior surface of the eye.
- the target is the choroid, e.g. , the approximate median depth of the choroid.
- the present invention describes delivering a therapeutic dose to a particular range of depths (as measured from the interface of the sclera and delivery device) .
- the depth ranges from 0.5 mm to 2.0 mm.
- the depth ranges from 0.75 mm to 2.0 mm.
- the depth ranges from 1.0 mm to 2.0 mm.
- the depth ranges from 0.5 mm to 1.5 mm.
- the present invention is not limited to the aforementioned depth ranges relevant to the therapeutic dose delivery.
- the choroid is within the range of depths to which the therapeutic dose (s) is delivered, e.g. , in some preferred embodiments, the depth of the target (e.g. , median depth of the choroid) is 1.25 mm from the interface of the sclera and delivery device, therefore the target receives the therapeutic dose.
- the choroid target is from 0.5 to 2 mm from the interface of the sclera and delivery device. In some preferred embodiments, the choroid target is from 0.75 to 1.5 mm from the interface of the sclera and delivery device. In some preferred embodiments, the choroid target is from 0.5 to 2 mm from the interface of the sclera and delivery device.
- the choroid target is from 1 to 1.5 mm from the interface of the sclera and delivery device. In some preferred embodiments, the choroid target is from 0.75 to 1.75 mm from the interface of the sclera and delivery device.
- a radiation dose delivered to the choriocapillaris of less than 10 Gy may induce intimal proliferation in larger choroidal vessels, thus reducing hyperpermeability of these vessels, while also minimizing damage to the choriocapillaris and other more radiosensitive structures of the eye.
- a novel episcleral brachytherapy device has been introduced by Salutaris Medical Devices, Inc. (SalutarisMD) to treat wet AMD with an accurate therapeutic dose. It employs a 90Sr/90Y source RBS encapsulated in a stainless steel holder which is loaded into the distal end of the applicator' s curved cannula. The device is introduced through the retrobulbar sub-Tenon route and radiation is delivered through the sclera to the CNV lesion over a matter of minutes (see FIG. 5) . A clinical trial to assess the safety and feasibility of the device in patients with wet AMD has been started and is expected to complete in 2022.
- Dose titration of the radiation is key to minimize the damage to the choriocapillaris and other radiosensitive structures of the eye, and to avoid radiation retinopathy, radiation maculopathy, radiation neuropathy, and cataract.
- Specialized devices for episcleral brachytherapy such as the SalutarisMD may be used in conjunction with the present invention in order to provide additional safety and ease of performing a procedure utilizing the present invention, thus making it more practical.
- the present invention may be used to treat chronic serous chorioretinopathy (CSCR) .
- the present invention features a radionuclide brachytherapy source (RBS) for use in a method of irradiating a target of an eye, the method comprising inserting said cannula into a potential space under a Tenon' s capsule of the eye, whereby the RBS is positioned over a choroid target at the back of the eye, wherein a therapeutic dose of radiation is delivered to the choroid target. A radioactive therapeutic portion of the RBS is consumed during the method.
- the RBS may be present in a delivery device, e.g. , in a cannula of a delivery device.
- the choroid target is from 0.5 to 2 mm from the interface of the sclera and delivery device. In some preferred embodiments, the choroid target is from 0.75 to 1.5 mm from the interface of the sclera and delivery device. In some preferred embodiments, the choroid target is from 0.5 to 2 mm from the interface of the sclera and delivery device. In some preferred embodiments, the choroid target is from 1 to 1.5 mm from the interface of the sclera and delivery device. In some preferred embodiments, the choroid target is from 0.75 to 1.75 mm from the interface of the sclera and delivery device.
- the therapeutic doses are generally selected such that intimal proliferation of large choroidal vessels is increased while damage to vessels of the choriocapillaris and other radiosensitive structures of the eye, such as the lens, are minimized.
- Other radiosensitive structures that it may be desirable to avoid radiation exposure to include the lens, the choriocapillaris, the retina, and retinal blood vessels.
- the therapeutic dose is from 6 to 18 Gy. In some preferred embodiments the therapeutic dose is 6-8 Gy. In some preferred embodiments the therapeutic dose is 6-10 Gy. In some preferred embodiments the therapeutic dose is 6-12 Gy. In some preferred embodiments the therapeutic dose is 6-
- the therapeutic dose is 8-10
- the therapeutic dose is 8-12 Gy.
- the therapeutic dose is 8-16 Gy. In some preferred embodiments the therapeutic dose is 8-18 Gy. In some preferred embodiments the therapeutic dose is 10-12 Gy. In some preferred embodiments the therapeutic dose is 10-14 Gy. In some preferred embodiments the therapeutic dose is 10-18 Gy . In some preferred embodiments the therapeutic dose is 12-16 Gy. In some preferred embodiments the therapeutic dose is 12-18 Gy. In some preferred embodiments the therapeutic dose is 14-18 Gy.
- the therapeutic dose is delivered to a particular depth or range of depths, e.g. , as measured from the interface of the sclera and the delivery device.
- the therapeutic dose delivered to a depth from 0.5 mm to 2 mm is from 6-18 Gy.
- the therapeutic dose delivered to a depth from 0.5 mm to 2 mm is from 6-16 Gy.
- the therapeutic dose delivered to a depth from 0.5 mm to 2 mm is from 6-14 Gy.
- the therapeutic dose delivered to a depth from 0.5 mm to 2 mm is from 6-12 Gy.
- the therapeutic dose delivered to a depth from 0.5 mm to 2 mm is from 8-18 Gy.
- the therapeutic dose delivered to a depth from 0.5 mm to 2 mm is from 8-16 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 0.5 mm to 2 mm is from 8-14 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 0.5 mm to 2 mm is from 8-12 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 0.75 mm to 1.75 mm is from 6-18 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 0.75 mm to 1.75 mm is from 6-16 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 0.75 mm to 1.75 mm is from 6-14 Gy.
- the therapeutic dose delivered to a depth from 0.75 mm to 1.75 mm is from 6-12 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 0.75 mm to 1.75 mm is from 8-18 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 0.75 mm to 1.75 mm is from 8-16 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 0.75 mm to 1.75 mm is from 8-14 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 0.75 mm to 1.75 mm is from 8-12 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 1 mm to 1.5 mm is from 6-18 Gy.
- the therapeutic dose delivered to a depth from 1 mm to 1.5 mm is from 6-16 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 1 mm to 1.5 mm is from 6-14 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 1 mm to 1.5 mm is from 6-12 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 1 mm to 1.5 mm is from 8-18 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 1 mm to 1.5 mm is from 8-16 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 1 mm to 1.5 mm is from 8-14 Gy.
- the therapeutic dose delivered to a depth from 1 mm to 1.5 mm is from 8-12 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 0.5 mm to 1.25 mm is from 6-18 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 0.5 mm to 1.25 mm is from 6-16 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 0.5 mm to 1.25 mm is from 6-14 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 0.5 mm to 1.25 mm is from 6-12 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 0.5 mm to 1.25 mm is from 8-18 Gy.
- the therapeutic dose delivered to a depth from 0.5 mm to 1.25 mm is from 8-16 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 0.5 mm to 1.25 mm is from 8-14 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 0.5 mm to 1.25 mm is from 8-12 Gy.
- the therapeutic dose is calculated based on the thickness of the choroid target.
- a thicker choroid target may dictate that a larger therapeutic dose is used.
- a thicker choroid target may dictate that a smaller therapeutic dose is used.
- the thickness of the choroid target is measured using imaging.
- the imaging may comprise optical coherence tomography (OCT) , optical coherence tomography (OCT) using enhanced depth imaging (EDI) , Spectral Domain Optical Coherence Tomography (SD- OCT) , Swept Source Optical Coherence Tomography (SS-OCT) , or Topcon Deep Range Imaging OCT.
- OCT optical coherence tomography
- OCT optical coherence tomography
- EDI enhanced depth imaging
- SD- OCT Spectral Domain Optical Coherence Tomography
- SS-OCT Swept Source Optical Coherence Tomography
- Topcon Deep Range Imaging OCT Topcon Deep Range Imaging
- the retina is exposed to less than 6 Gy. In some preferred embodiments, the retina is exposed to less than 8 Gy. In some preferred embodiments, a choriocapillaris is exposed to less than 8 Gy. In some preferred embodiments, a choriocapillaris is exposed to less than 10 Gy. In some preferred embodiments, an interface of large choroidal vessels and a choriocapillaris is exposed to less than 10 Gy. In some preferred embodiments, an interface of large choroidal vessels and a choriocapillaris is exposed to less than 12 Gy. In some preferred embodiments, the retina is exposed to less radiation than the choroid target.
- a choriocapillaris is exposed to less radiation than the choroid target.
- a lens is exposed to less radiation than the choroid target.
- a retinal blood vessel is exposed to less radiation than the choroid target .
- the dose is delivered to the choroid target in a period of time, e.g. , a dwell time.
- the dwell time is from 5 seconds to 10 minutes.
- the dwell time is from 5 seconds to 15 second.
- the dwell time is from 5 seconds to 30 seconds.
- the dwell time is from 5 seconds to 45 seconds.
- the dwell time is from 5 seconds to 1 minute.
- the dwell time is from 5 seconds to 2 minutes.
- the dwell time is from 15 seconds to 30 seconds.
- the dwell time is from 15 seconds to 1 minute.
- the dwell time is from 15 seconds to 90 seconds.
- the dwell time is from 15 seconds to 2 minutes. In some preferred embodiments, the dwell time is from 30 seconds to 1 minute. In some preferred embodiments, the dwell time is from 1 minute to 90 seconds. In some preferred embodiments, the dwell time is from 1 minute to 2 minutes. In some preferred embodiments, the dwell time is from 90 seconds to 2 minutes. In some preferred embodiments, the dwell time is from 2 to 4 minutes. In some preferred embodiments, the dwell time is from 4 to 6 minutes. In some preferred embodiments, the dwell time is from 6 to 8 minutes. In some preferred embodiments, the dwell time is from 8 to 10 minutes. In some preferred embodiments the dwell time is from 5 to 10 minutes. In some preferred embodiments, the dwell time is greater than 10 minutes.
- the RBS delivers radiation to an irradiated area.
- the diameter of the irradiated area is up to 8 millimeters. In some preferred embodiments, the diameter of the irradiated area is up to 12 millimeters. In some preferred embodiments, the diameter of the irradiated area is 3-5 millimeters. In some preferred embodiments, the diameter of the irradiated area is 1-3 millimeters. In some preferred embodiments, the diameter of the irradiated area is 5-7 millimeters. In some preferred embodiments, the diameter of the irradiated area is 7-9 millimeters. In some preferred embodiments, the diameter of the irradiated area is 9-12 millimeters.
- the RBS is a source of ionizing radiation. In some preferred embodiments, the RBS is a source of particle radiation. In some preferred embodiments, the RBS is a source of beta radiation. In some preferred embodiments, the RBS is a source of alpha radiation. In some preferred embodiments, the RBS is a source of neutron radiation. In some preferred embodiments, the RBS is a source of X-ray radiation. In some preferred embodiments, the RBS is a source of other electromagnetic radiation. In some preferred embodiments, the RBS is a source of multiple types of radiation.
- the present invention also features a method of reducing hyperpermeability of large choroidal vessels in an eye of a patient in need thereof with central serous chorioretinopathy.
- the method comprises inserting a cannula into a potential space under a Tenon' s capsule of the eye of the patient, the cannula having a radionuclide brachytherapy source (RBS) at a treatment position, whereby the RBS is positioned over a choroid target, and wherein a therapeutic dose of radiation is delivered to the choroid target.
- RBS radionuclide brachytherapy source
- a reduction in hyperpermeability will result in less fluid accumulation under the retina, thus treating CSCR.
- the present invention also features a method of increasing collagen deposition associated with large choroidal vessels in an eye of a patient in need thereof with central serous chorioretinopathy.
- the method comprises inserting a cannula into a potential space under a Tenon' s capsule of the eye of the patient, the cannula having a radionuclide brachytherapy source (RBS) at a treatment position, whereby the RBS is positioned over a choroid target, and wherein a therapeutic dose of radiation is delivered to the choroid target.
- RBS radionuclide brachytherapy source
- an increase in collagen deposition associated with large choroidal vessels will cause a reduction in hyperpermeability that will result in less fluid accumulation under the retina, thus treating CSCR.
- the present invention also features a method of treating central serous chorioretinopathy in a patient in need thereof.
- the method comprises inserting a cannula into a potential space under a Tenon' s capsule of an eye of the patient, the cannula having a radionuclide brachytherapy source (RBS) at a treatment position, whereby the RBS is positioned over a choroid target, and wherein a therapeutic dose of radiation is delivered to the choroid target.
- RBS radionuclide brachytherapy source
- treating CSCR may be accomplished by inducing a reduction in hyperpermeability of large choroidal vessels and/or increasing collagen deposition associated with large choroidal vessels and/or reducing fluid accumulation under the retina.
- the dose delivered is such that radiation retinopathy is avoided. In some preferred embodiments, the dose delivered is such that radiation choroidopathy is avoided. In some preferred embodiments, the dose delivered is such that radiation maculopathy is avoided. In some preferred embodiments, the dose delivered is such that radiation neuropathy is avoided. In some preferred embodiments, the dose delivered is such that cataract is avoided. In some preferred embodiments, the dose delivered is such that choroidal neovascularization is avoided. In some preferred embodiments, the dose delivered is such that other adverse events of radiation therapy are avoided.
- the therapeutic dose to be administered may be calculated a priori before any treatment course (or a portion thereof) is delivered.
- the therapeutic dose to be administered may be fractionated (e.g., divided and delivered) over a number of sessions.
- the therapeutic dose is fractionated over at least 2 sessions.
- the therapeutic dose is fractionated over 2 sessions.
- the therapeutic dose is fractionated over 3 sessions.
- the therapeutic dose is fractionated over 4 sessions.
- the therapeutic dose is fractionated over more than 4 sessions.
- the sessions are divided into a time frame of 1 week. In some preferred embodiments, the sessions are divided into a time frame of 2 weeks.
- the sessions are divided into a time frame of 3 weeks. In some preferred embodiments, the sessions are divided into a time frame of 4 weeks. In some preferred embodiments, the sessions are separated by 1 to 7 days. In some preferred embodiments, the sessions are separated by 5 to 10 days. In some preferred embodiments, the sessions are separated by 5 to 14 days. In some preferred embodiments, the sessions are separated by 5 to 21 days .
- the patient is reassessed after a period of time following the first treatment course to determine if the patient needs a second treatment course.
- the patient may also be reassessed after additional treatment courses as well, for example, in some preferred embodiments, the patient is reassessed following a second treatment course to determine if the patient needs a third treatment course.
- the time frame between two particular treatment courses e.g. , a first treatment course and a second treatment course, a second treatment course and a third treatment course, etc.
- the time frame between two particular treatment courses is 3-12 months.
- the time frame between two particular treatment courses is 3-6 months.
- the time frame between two particular treatment courses is 6 to 12 months.
- the time frame between two particular treatment courses is 3 to 24 months. In some preferred embodiments, the time frame between two particular treatment courses is 3 to 36 months. In some preferred embodiments, the time frame between two particular treatment courses is greater than a year. In some preferred embodiments, the time frame between two particular treatment courses is greater than 2 years. In some preferred embodiments, the time frame between two particular treatment courses is greater than 3 years.
- the first treatment course may be fractionated, e.g. , divided and delivered over the course of at least 2 sessions.
- the second (or third or subsequent courses) may also be fractionated over at least 2 sessions.
- the RBS is contained within a cannula.
- the cannula is part of a delivery device, wherein the delivery device comprises: a cannula comprising a curved distal portion adapted for placement around a portion of a globe of an eye; a curved proximal portion, the curved distal portion and the curved proximal portions being connected with each other at an inflection point where the direction of the curvature changes sign; and a straight proximal portion, wherein (a) the distal portion has a radius of curvature between about 9 mm to 15 mm and an arc length between about 25 mm to 35 mm; and (b) the proximal portion has a radius of curvature between about an inner cross-sectional radius of the cannula and about 1 meter; and wherein an angle 91 between a line 13 tangent to the distal portion and to the curved proximal portion at the inflection point and the straight
- the present application incorporates the following patent applications in their entirety herein by reference:
- the present invention features the use of specialized delivery devices such as but not limited to those described in US Patent Application No: 10/836, 140; US Patent Application No: 12/350, 079; US Patent Application No: 12/497, 644; US Patent Application No: 13/111, 765; US Patent Application No: 13/111, 780; US Patent Application No: 13/742, 823; US Patent Application No: 13/872, 941; US Patent Application No: 13/953, 528; US Patent Application No: 14/011, 516; US Patent Application No: 14/486, 401; US Patent Application No: 14/687, 784; US Patent Application No: 15/871,756; US Patent Application No: 15/023, 196; US Patent Application No: 15/004, 538; US Patent Application No: 15/628, 952; US Patent Application No: 16/015, 892; US Patent Application No: 16/009, 646; U.S.
- FIG. 5, FIG. 6, FIG. 7A, FIG. 7B, FIG. 7C, and FIG. 7D show non-limiting examples of cannulas.
- the system comprises a cannula (e.g. , as part of a delivery device) .
- the cannula (100) comprises a curved distal portion (110) adapted for placement around a portion of a globe of an eye; a curved proximal portion (120) , the curved distal portion and the curved proximal portions being connected with each other at an inflection point (130) where the direction of the curvature changes sign.
- the cannula comprises a straight proximal portion.
- the distal portion has a radius of curvature (180) between about 9 mm to 15 mm and an arc length between about 25 mm to 35 mm; and the proximal portion has a radius of curvature (190) between about an inner cross-sectional radius of the cannula and about 1 meter; and the angle 0i (425) between a line (420) tangent to the distal portion and to the curved proximal portion at the inflection point and the straight proximal portion is between greater than about 0 degrees to about 180 degrees.
- the present invention may be used to treat macular edema.
- the present invention features a radionuclide brachytherapy source (RBS) for use in a method of irradiating a target of an eye, wherein said RBS is present in a cannula of a delivery device, the method comprising inserting said cannula into a potential space under a Tenon' s capsule of the eye, whereby the RBS is positioned over a target at the back of the eye, wherein a therapeutic dose of radiation is delivered to the target, wherein a radioactive therapeutic portion of the RBS is consumed during the method.
- the therapeutic dose may range from 6 to 24 Gy.
- the target is a blood vessel.
- the target is located in the choroid.
- the target is located outside of the choroid.
- the present invention may be used to treat diabetic retinopathy (DR) .
- the present invention features a radionuclide brachytherapy source (RBS) for use in a method of irradiating a target of an eye, wherein said RBS is present in a cannula of a delivery device, the method comprising inserting said cannula into a potential space under a Tenon' s capsule of the eye, whereby the RBS is positioned over a target at the back of the eye, wherein a therapeutic dose of radiation is delivered to the target, wherein a radioactive therapeutic portion of the RBS is consumed during the method.
- the therapeutic dose may range from 6 to 24 Gy.
- the target is a blood vessel.
- the target is located in the choroid.
- the target is located outside of the choroid.
- the present invention may be used to treat central macular edema (CME) .
- the present invention features a radionuclide brachytherapy source (RBS) for use in a method of irradiating a target of an eye, wherein said RBS is present in a cannula of a delivery device, the method comprising inserting said cannula into a potential space under a Tenon's capsule of the eye, whereby the RBS is positioned over a target at the back of the eye, wherein a therapeutic dose of radiation is delivered to the target, wherein a radioactive therapeutic portion of the RBS is consumed during the method.
- the therapeutic dose may range from 6 to 24 Gy.
- the target is a blood vessel.
- the target is located in the choroid.
- the target is located outside of the choroid.
- the present invention may be used to treat macular edema (ME) secondary to central retinal vein occlusion (CRVO) .
- the present invention features a radionuclide brachytherapy source (RBS) for use in a method of irradiating a target of an eye, wherein said RBS is present in a cannula of a delivery device, the method comprising inserting said cannula into a potential space under a Tenon' s capsule of the eye, whereby the RBS is positioned over a target at the back of the eye, wherein a therapeutic dose of radiation is delivered to the target, wherein a radioactive therapeutic portion of the RBS is consumed during the method.
- RBS radionuclide brachytherapy source
- the therapeutic dose may range from 6 to 24 Gy.
- the target is a blood vessel.
- the target is located in the choroid. In some preferred embodiments, the target is located outside of the choroid.
- the present invention may be used to treat macular edema (ME) secondary to branch retinal vein occlusion (BRVO) .
- ME macular edema
- BRVO retinal vein occlusion
- the present invention features a radionuclide brachytherapy source (RBS) for use in a method of irradiating a target of an eye, wherein said RBS is present in a cannula of a delivery device, the method comprising inserting said cannula into a potential space under a Tenon' s capsule of the eye, whereby the RBS is positioned over a target at the back of the eye, wherein a therapeutic dose of radiation is delivered to the target, wherein a radioactive therapeutic portion of the RBS is consumed during the method.
- the therapeutic dose may range from 6 to 24 Gy.
- the target is a blood vessel.
- the target is located in the choroid. In some preferred embodiments, the target is located outside of the choroid.
- the present invention features a method of reducing hyperpermeability of large choroidal vessels in an eye of a patient in need thereof with at least one condition selected from the following: macular edema, diabetic retinopathy, diabetic macular edema, cystoid macular edema, macular edema secondary to central retinal vein occlusion, or macular edema secondary to branch retinal vein occlusion, said method comprising inserting a cannula into a potential space under a Tenon' s capsule of the eye of the patient, the cannula having a radionuclide brachytherapy source (RBS) at a treatment position, whereby the RBS is positioned over a target, and wherein a therapeutic dose of radiation is delivered to the target.
- RBS radionuclide brachytherapy source
- the therapeutic dose may range from 6 to 24 Gy.
- the target is a blood vessel. In some preferred embodiments, the target is located in the choroid. In some preferred embodiments, the target is located outside of the choroid.
- the present invention features a method of increasing collagen deposition associated with large choroidal vessels in an eye of a patient in need thereof with at least one condition selected from the following: macular edema, diabetic retinopathy, diabetic macular edema, cystoid macular edema, macular edema secondary to central retinal vein occlusion, or macular edema secondary to branch retinal vein occlusion, said method comprising inserting a cannula into a potential space under a Tenon' s capsule of the eye of the patient, the cannula having a radionuclide brachytherapy source (RBS) at a treatment position, whereby the RBS is positioned over a target, and wherein a therapeutic dose of radiation is delivered to the target.
- RBS radionuclide brachytherapy source
- the therapeutic dose may range from 6 to 24 Gy.
- the target is a blood vessel. In some preferred embodiments, the target is located in the choroid. In some preferred embodiments, the target is located outside of the choroid.
- the present invention features a method of treating at least one condition selected from the following: macular edema, diabetic retinopathy, diabetic macular edema, cystoid macular edema, macular edema secondary to central retinal vein occlusion, or macular edema secondary to branch retinal vein occlusion in a patient in need thereof, said method comprising inserting a cannula into a potential space under a Tenon' s capsule of an eye of the patient, the cannula having a radionuclide brachytherapy source (RBS) at a treatment position, whereby the RBS is positioned over a target, and wherein a therapeutic dose of radiation is delivered to the target.
- RBS radionuclide brachytherapy source
- the therapeutic dose may range from 6 to 24 Gy.
- the target is a blood vessel. In some preferred embodiments, the target is located in the choroid. In some preferred embodiments, the target is located outside of the choroid.
- the dose delivered is such that radiation retinopathy is avoided. In some preferred embodiments, the dose delivered is such that radiation choroidopathy is avoided. In some preferred embodiments, the dose delivered is such that radiation maculopathy is avoided. In some preferred embodiments, the dose delivered is such that radiation neuropathy is avoided. In some preferred embodiments, the dose delivered is such that cataract is avoided. In some preferred embodiments, the dose delivered is such that choroidal neovascularization is avoided. In some preferred embodiments, the dose delivered is such that adverse effects are avoided.
- references to the below claims are solely for ease of examination of this patent application, and are exemplary, and are not intended in any way to limit the scope of the claims to the particular features having the corresponding reference numbers in the drawings.
Landscapes
- Health & Medical Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Organic Chemistry (AREA)
- Surgery (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Radionuclide brachytherapy sources (RBS) for applying radiation to a target area, for example for treating macular edema (ME), diabetic retinopathy (DR), diabetic macular edema (DME), cystoid macular edema (CME), ME secondary to central retinal vein occlusion (CRVO), and ME secondary to branch retinal vein occlusion (BRVO). The RBSs provided herein are useful for decreasing vascular permeability while minimizing adverse effects associated with radiotherapy, thereby providing advantages over existing brachytherapy sources.
Description
RADIONUCLIDE BRACHYTHERAPY SOURCE SYSTEMS
FOR OCULAR RADIOTHERAPY
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of U.S. Patent Application No. 63/381, 454, filed on October 28, 2022. The entire contents of this application are hereby incorporated by reference.
BACKGROUND OF THE INVENTION
1. Field of the Invention
[0002] This invention relates to the field of radiotherapy and more specifically to the subfield of brachytherapy, and to radionuclide brachytherapy sources (RBS) used to treat conditions of the eye, such as but not limited to diabetic retinopathy (DR) , diabetic macular edema (DME) , cystoid macular edema (CME) , macular edema (ME) secondary to central retinal vein occlusion (CRVO) , and ME secondary to branch retinal vein occlusion (BRVO) .
2. Description of the Related Art
[0003] Central Serous Chorioretinopathy (CSCR) is a condition affecting the eye, which may result in visual impairment and typically presents unilaterally in one eye, but bilateral involvement may be present in up to 40% of cases. CSCR typically causes blurred or distorted vision, e.g. , metamorphopsia . Patients may also report micropsia (objects appearing smaller than they really are) and/or color vision disturbances. Temporary hyperopia (farsightedness) is generally present. CSCR may also cause a blurred or gray spot in the central visual field, which commonly occurs when the retina is detached. Reduced visual acuity may resolve upon resolution of CSCR, or may persist after the fluid
accumulation that is associated with CSCR has dispersed and CSCR has resolved.
[0004] CSCR is generally regarded as being of unknown cause, and mostly affects white males aged 20-50 years of age. It is believed that CSCR is associated with exogenous corticosteroid use. Further, CSCR is also believed to be associated with psychological stress, which in turn is associated with increased endogenous cortisol levels. Furthermore, other conditions associated with increased endogenous cortisol production, for example, Cushing syndrome and pregnancy, are also associated with an increased risk of developing CSCR. Cortisol is an endogenous glucocorticoid corticosteroid produced by the adrenal cortex, more specifically the zona fasciculata. Thus, it is believed that there is a general association between increased corticosteroid levels, whether from exogenous or endogenous sources, and the development of CSCR.
[0005] CSCR is characterized by an accumulation of fluid under the retina. In particular, fluid has the propensity to accumulate under the macula, an oval area surrounding the fovea, a small depression in the retina where retinal cones are particularly concentrated and where visual acuity is highest. The source of this fluid is typically hyperpermeable large vessels of the choroid, e.g. , large choroidal vessels. Serous fluid, leaked from the choroid, accumulates under the retina, causing small and localized detachments of the neurosensory layer of the macula (a part of the retina) , with or without concomitant detachment of the retinal pigment epithelium (RPE) , e.g., with or without pigment epithelial detachment (PED) . Detachment of the neurosensory layer results in the acute or chronic symptoms of met amorphopsia and other visual changes associated with CSCR.
[0006] The choroid is the vascular layer of the eye, sitting between the retina (deep to the choroid) and the sclera
(superficial to the choroid) . The choroid provides blood flow to much of the retina. The choroid is divided into four layers. From most superficial (farthest from the retina) to deepest (closest to the retina) , the layers are: Haller' s layer, Sattler' s layer, choriocapillaris, and Bruch' s membrane. Haller's layer is the outermost (most superficial) layer of the choroid, and contains the largest choroidal vessels. Sattler' s layer is deep to Haller' s layer, and contains medium-sized choroidal vessels. The choriocapillaris is deep to Sattler' s layer, and contains capillaries, e.g. , small vessels. Bruch' s membrane is the innermost (e.g. , deepest) layer of the choroid, contains small vessels, and contains the basement membrane of both the choriocapillaris (on its most outermost side) and the basement membrane of the retinal pigment epithelium (on its innermost side) . [0007] The primary disease process involved in CSCR is serous fluid leakage from large choroidal vessels, subsequent fluid accumulation under the macula, and resultant detachment of the neurosensory layer of the macula, with or without PED. However, the pathophysiology of CSCR is multifactorial. Choroidal inflammation leads to vessel stasis, hyperpermeability, and thickening of the choroid. Thus, characteristic intermediate elements of CSCR' s pathology are choroidal hyperpermeability and choroidal thickening. In turn, increased tissue pressure on the RPE results, which results in damage to the RPE and may cause PED. Damage to the RPE decreases its effectiveness as a barrier, and choroidal fluid can thus cross the RPE, resulting in detachment of the neurosensory layer.
[0008] Furthermore, it is hypothesized that CSCR may result in the loss of polarity of the RPE. In a healthy eye, the RPE pumps fluid from the subretinal space into the choroid, keeping the retina in a relatively "dry" state. However, if polarity loss occurs, the RPE may reverse its pumping direction, pumping fluid
from the choroid into the subretinal space. This may lead to subretinal fluid accumulation. Furthermore, choriocapillaris attenuation and hypoperfusion may result in elevated hydrostatic pressure and a resultant decrease in reabsorption performed by capillaries of the choriocapillaris. Again, this may contribute to subretinal fluid accumulation.
[0009] It is believed that mineralocorticoid receptors may also play a role, though their potential role is currently not well- defined. Experimental results have shown that intravitreal aldosterone injection results in dilatation of choroidal veins and choroidal congestion, which leads to subretinal fluid accumulation .
[0010] CSCR resolves spontaneously in the majority of cases and normal vision is regained, however recurrent retinal detachment is common. Because the condition is generally self-resolving, most clinicians will observe the patient for three to six months while attempting to correct any predisposing factors (e.g., tapering and stopping exogenous steroids, reducing the patient' s stress, etc.) . If CSCR and associated symptoms persist for over three to six months, or if detachment reoccurs, CSCR may be classified as chronic CSCR. Chronic CSCR leads to permanent pathophysiological changes, e.g. , foveal atrophy and changes to the retinal pigment epithelium. Chronic cases, if untreated, lead to permanent vision loss. Therefore, treatment is indicated for chronic CSCR. The most widely-utilized prior art treatments with the greatest level of evidence are laser photocoagulation and photodynamic therapy (PDT) .
[0011] Laser photocoagulation uses a laser to emit light which is absorbed by the targeted tissue, raising the tissue' s temperature and causing subsequent denaturation of proteins. Leakage sites on the retinal pigment epithelium are visualized with angiography and indicated by sites of hyperfluorescence, and
these sites are then targeted with the laser. The leakage point is thus sealed, which decreases the time until subretinal fluid is cleared. However, laser photocoagulation suffers from several shortcomings. Laser photocoagulation is not an option if retinal pigment epithelial detachments involve the fovea, as the laser may cause permanent vision loss if used on the fovea. Laser photocoagulation is not proven to reduce the chance of recurrence of CSCR. Laser photocoagulation results in destruction of surrounding healthy retinal tissue, and may thus lead to the development of scotomas (spots of total or partial blindness in an otherwise normal field of vision) . Laser photocoagulation may also lead to choroidal neovascularization and further vision loss, particularly if the Bruch' s membrane is damaged by the laser. The potential development of these adverse effects thus requires frequent ophthalmological follow up for patients who have undergone laser photocoagulation. Laser photocoagulation is now considered an outdated treatment methodology by many clinicians .
[0012] Photodynamic therapy (PDT) is another option to treat CSCR. PDT is especially preferred over laser photocoagulation in cases where there is a leak on or near the fovea, where there are multiple leaks, and where there is diffuse decompensation of the retinal pigment epithelium. Verteporfin, a photosensitizer, is injected intravenously. Verteporfin reaches the eye via the bloodstream and is activated by light with a wavelength of 689 nm, producing short-lived reactive oxygen species and causing local damage and blockage of blood vessels in areas targeted by the light source. PDT thus seals sources of choroidal leaks, and results in choroidal vascular remodeling and choroidal hypoperfusion, further reducing choroidal hyperpermeability. PDT is generally considered to be more effective and safer than laser photocoagulation. Low fluence or half-fluence PDT, or low-dose or half-dose PDT (using a lower or half dose of verteporfin) has been found to be equally
effective as standard fluence or standard dose PDT, with a more favorable adverse effect profile. However, PDT is still associated with shortcomings, such as a need to minimize UV exposure following treatment and photosensitivity. Standard fluence PDT has also been associated with significant damage to the choriocapillaris , although reduced-fluence PDT has decreased the prevalence of this complication .
[0013] Other treatments for CSCR have been tested with mixed results. Use of eplerenone, a mineralocorticoid antagonist, has been explored because of the potential role of mineralocorticoids in the development of CSCR. Epelerenone was found not superior to placebo in chronic CSCR (Lotery, A. et al. (2020) Lancet 395 (10220) , 294-303) . Other attempts at using ant i-cort icosteroid treatments have included finasteride, a 5a-reductase inhibitor with anti-androgenic properties, mifepristone, an antiprogesterone abort if acient , and rifampin, an ant itubercular antibiotic that accelerates the metabolism of corticosteroids in the liver by acting as a potent inducer of CYP3A4, the main enzyme responsible for steroid catabolism. However, studies on these agents have generally been small, results have generally been inconclusive, and none of these agents are currently considered standard of care. The same is true of anti-adrenergic agents that have been tested, for example, the selective beta-blocker metoprolol. Anti-VEGF therapy, including intravitreal injections with anti-VEGF agents like bevacizumab, has shown a lack of benefit in CSCR. The rationale for the use of anti-VEGF agents in CSCR has been widely questioned, because there is no known overexpression of VEGF in CSCR and CSCR is generally not associated with angiogenesis or neovascularization. Thus, the pharmacological rationale for anti-VEGF use in CSCR is generally considered lacking. Conflicting evidence or a general lack of demonstrated efficacy has thus confined most treatment of CSCR to either laser
photocoagulation (a more limited treatment, considered outdated by some clinicians) or PDT (which is generally preferred over laser photocoagulation) .
[0014] Diabetes mellitus (DM) is the leading cause of blindness in the United States for people between 20 and 74 years of age. Patients with DM are 25 times more likely to become legally blind than patients without DM. DM may lead to diabetic retinopathy (DR) . DR may lead to diabetic macular edema (DME) and neovascularization. [0015] There are two stages of DR: non-proliferat ive and proliferative. Non-proliferat ive DR typically presents late in the first decade or early in the second decade of DR and is characterized by retinal vascular microaneurysms, blot hemorrhages, and cotton-wool spots. More severe forms of nonproliferative DR may be characterized by changes in venous vessel caliber, intraretinal microvascular abnormalities, and more numerous microaneurysms and hemorrhages. Non-proliferat ive DR' s pathophysiology is defined by loss of retinal pericytes, increased retinal vascular permeability, alterations to retinal blood flow, and abnormal retinal microvasculature, all of which may lead to retinal ischemia.
[0016] Proliferative DR features neovascularization in response to retinal hypoxemia. Newly formed vessels appear near the optic nerve and/or macula and rupture easily, in turns causing vitreous hemorrhage, fibrosis, and retinal detachment.
[0017] Non-proliferat ive DR does not always evolve into proliferative DR, however the greater the severity of nonproliferative DR, the greater the likelihood of it evolving into proliferative DR within five years.
[0018] Both proliferative and non-proliferat ive DR may be associated with the development of clinically significant diabetic macular edema (DME) . DME is associated with a 25% chance of moderate vision loss over three years. The duration of DM and the
degree of glycemic control are the primary factors that determine risk of developing retinopathy, though other factors such as hypertension, nephropathy, dyslipidemia, and genetics also play a smaller role.
[0019] The most effective existing approach for handling DR has been prevention via glycemic and blood pressure control in individuals with Type 1 or Type 2 DM. Interestingly, improved glycemic control is associated with transiently worsened DR during the first six to 12 months of improved control, though this is temporary and in the long-term, improved glycemic control is associated with improvements in DR.
[0020] Pharmacological treatments for DR include fenofibrate, which slows the progression of DR, and anti-VEGF therapy delivered via ocular injection, which may help preserve vision. Interventional procedures for DR include laser photocoagulation, which may also help preserve vision.
[0021] Cystoid macular edema (CME) is a retinal thickening of the macula due to disruption of the normal function of the blood- retinal barrier, leading to leakage of perifoveal retinal capillaries and subsequent accumulation of fluid with the intracellular spaces of the retina. Loss of vision occurs via retinal thickening and fluid collection that distorts the photoreceptors. A balance between osmotic pressure, hydrostatic force, capillary permeability, and tissue compliance maintains the normal retinal environment. An imbalance between capillary filtration rate and fluid removal from the retinal extracellular space may result in fluid accumulation in the cystoid spaces in the inner layers of the retina, particularly the outer plexiform layer (OPL) .
[0022] Vit reomacular traction (VMT) can exert fractional force on retinal cells, in turn causing release of inflammatory mediators, e.g., basic fibroblastic growth factor (bFGF) , vascular
endothelial growth factor (VEGF) , and platelet derived growth factor (PDGF) . These in turn cause breakdown of the blood-retinal barrier and separation of the retina and RPE, lysis of Muller cells, and fluid leakage and edema. Foveal edema and retinal thickening typically result.
[0023] Prior art treatments of CME vary depending on the etiology of CME. Many cases of CME are self-limiting and do not require treatment. If CME persists over 3-4 months, treatment may be indicated. Medical treatment has included NSAIDs (to decrease prostaglandin production, as E2-prostaglandins are implicated in causing disruption of tight junctions in retinal capillaries) , corticosteroids (including corticosteroid-based intravitreal implants) , carbonic anhydrase inhibitors (help move fluid out of the retinal intracellular spaces) , and anti-VEGF agents. Surgical treatments in the prior art have included pars plana vitrectomy (PPV) , which has uneven efficacy depending on etiology (particularly in CME with significant nontract ional components) , and has the downside of being invasive. Other less-frequent ly utilized surgical treatments include laser photocoagulation, cryopexy, and various glaucoma-related procedures.
[0024] Central Retinal Vein Occlusion (CRVO) may also cause ME. CRVO is a form of retinal vein occlusion. It is a vascular occlusion of the central retinal vein, which in turn results in largely the same pathophysiological features of CME (listed above) , namely macular edema, retinal ischemia, and neovascular complications including glaucoma, vitreous hemorrhage, and retinal traction .
[0025] Prior art treatments of ME secondary to CRVO have included anti-VEGF and corticosteroids (injections or implants) to manage neovascularization and macular edema, respectively. Anti- VEGF injections are first-line therapy, and corticosteroids are generally second-line therapy. Panretinal photocoagulation has
been used to treat neovascularization of the iris associated with ME secondary to CRVO .
[0026] Branch Retinal Vein Occlusion (BRVO) may also cause ME. BRVO is a form of retinal vein occlusion. It is a vascular occlusion of any branch of the central retinal vein, which in turn results in the largely the same pathophysiological features of CME (listed above) , namely macular edema, retinal ischemia, and neovascular complications including glaucoma, vitreous hemorrhage, and retinal traction.
[0027] Prior art treatments of ME secondary to BRVO have included anti-VEGF and corticosteroids (injections or implants) to manage neovascularization and macular edema, respectively. Anti- VEGF injections are first-line therapy, and corticosteroids are generally second-line therapy. Grid laser photocoagulation may be used to manage macular edema secondary to BRVO.
SUMMARY OF THE INVENTION
[0028] Preferred embodiments of the present invention provide devices and compositions that allow for irradiating a choroid target in an eye, as specified in the independent claims. Preferred embodiments of the invention are given in the dependent claims. Preferred embodiments of the present invention can be freely combined with each other if they are not mutually exclusive.
[0029] The present invention may be used to treat chronic serous chorioretinopathy (CSCR) . For example, the present invention features a radionuclide brachytherapy source (RBS) for use in a method of irradiating a target of an eye, wherein said RBS is present in a cannula of a delivery device, the method comprising inserting said cannula into a potential space under a Tenon' s capsule of the eye, whereby the RBS is positioned over a choroid target at the back of the eye, wherein a therapeutic dose of radiation is delivered to the choroid target, wherein a radioactive
therapeutic portion of the RBS is consumed during the method.
[0030] Without wishing to limit the present invention to any theory or mechanism, the therapeutic doses are generally selected such that intimal proliferation of large choroidal vessels is increased while damages to vessels of the choriocapillaris and other radiosensitive structures of the eye, such as the lens, are minimized .
[0031] In some preferred embodiments, the therapeutic dose is from 6 to 18 Gy. In some preferred embodiments the therapeutic dose is 6-8 Gy. In some preferred embodiments the therapeutic dose is 6-10 Gy. In some preferred embodiments the therapeutic dose is 6-12 Gy. In some preferred embodiments the therapeutic dose is 6- 16 Gy. In some preferred embodiments the therapeutic dose is 8-10
Gy. In some preferred embodiments the therapeutic dose is 8-12 Gy.
In some preferred embodiments the therapeutic dose is 8-16 Gy. In some preferred embodiments the therapeutic dose is 8-18 Gy. In some preferred embodiments the therapeutic dose is 10-12 Gy. In some preferred embodiments the therapeutic dose is 10-14 Gy. In some preferred embodiments the therapeutic dose is 10-18 Gy. In some preferred embodiments the therapeutic dose is 12-16 Gy. In some preferred embodiments the therapeutic dose is 12-18 Gy. In some preferred embodiments the therapeutic dose is 14-18 Gy.
[0032] The therapeutic dose is delivered to a particular depth or range of depths, e.g., as measured from the interface of the sclera and the delivery device. For example, in some preferred embodiments, the therapeutic dose delivered to a depth from 0.5 mm to 2 mm is from 6-18 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 0.5 mm to 2 mm is from 6-16 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 0.5 mm to 2 mm is from 6-14 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 0.5 mm to 2 mm is from 6-12 Gy. In some preferred embodiments,
the therapeutic dose delivered to a depth from 0.5 mm to 2 mm is from 8-18 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 0.5 mm to 2 mm is from 8-16 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 0.5 mm to 2 mm is from 8-14 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 0.5 mm to 2 mm is from 8-12 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 0.75 mm to 1.75 mm is from 6-18 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 0.75 mm to 1.75 mm is from 6-16 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 0.75 mm to 1.75 mm is from 6-14 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 0.75 mm to 1.75 mm is from 6-12 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 0.75 mm to 1.75 mm is from 8-18 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 0.75 mm to 1.75 mm is from 8-16 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 0.75 mm to 1.75 mm is from 8-14 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 0.75 mm to 1.75 mm is from 8-12 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 1 mm to 1.5 mm is from 6-18 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 1 mm to 1.5 mm is from 6-16 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 1 mm to 1.5 mm is from 6-14 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 1 mm to 1.5 mm is from 6-12 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 1 mm to 1.5 mm is from 8-18 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 1 mm to 1.5 mm is from 8-16 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 1 mm to 1.5 mm is from 8-14 Gy. In some
preferred embodiments, the therapeutic dose delivered to a depth from 1 mm to 1.5 mm is from 8-12 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 0.5 mm to 1.25 mm is from 6-18 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 0.5 mm to 1.25 mm is from 6-16 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 0.5 mm to 1.25 mm is from 6-14 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 0.5 mm to 1.25 mm is from 6-12 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 0.5 mm to 1.25 mm is from 8-18 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 0.5 mm to 1.25 mm is from 8-16 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 0.5 mm to 1.25 mm is from 8-14 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 0.5 mm to 1.25 mm is from 8-12 Gy.
[0033] In some preferred embodiments, the therapeutic dose is calculated based on the thickness of the choroid target. In some preferred embodiments, the thickness of the choroid target is measured using imaging.
[0034] In some preferred embodiments, the retina is exposed to less than 8 Gy. In some preferred embodiments, a choriocapillaris is exposed to less than 10 Gy. In some preferred embodiments, an interface of large choroidal vessels and a choriocapillaris is exposed to less than 12 Gy. In some preferred embodiments, the retina is exposed to less radiation than the choroid target. In some preferred embodiments, a choriocapillaris is exposed to less radiation than the choroid target.
[0035] As will be described herein, in some preferred embodiments, the therapeutic dose is fractionated over multiple sessions. For example, the therapeutic dose may be fractionated over at least two sessions.
[0036] The dose is delivered to the choroid target in a period of time, e.g. , a dwell time. In some preferred embodiments, the dwell time is from 5 seconds to 10 minutes. In some preferred embodiments, the dwell time is from 5 seconds to 15 second. In some preferred embodiments, the dwell time is from 5 seconds to 30 seconds. In some preferred embodiments, the dwell time is from 5 seconds to 45 seconds. In some preferred embodiments, the dwell time is from 5 seconds to 1 minute. In some preferred embodiments, the dwell time is from 5 seconds to 2 minutes. In some preferred embodiments, the dwell time is from 15 seconds to 30 seconds. In some preferred embodiments, the dwell time is from 15 seconds to 1 minute. In some preferred embodiments, the dwell time is from 15 seconds to 90 seconds. In some preferred embodiments, the dwell time is from 15 seconds to 2 minutes. In some preferred embodiments, the dwell time is from 30 seconds to 1 minute. In some preferred embodiments, the dwell time is from 1 minute to 90 seconds. In some preferred embodiments, the dwell time is from 1 minute to 2 minutes. In some preferred embodiments, the dwell time is from 90 seconds to 2 minutes. In some preferred embodiments, the dwell time is from 2 to 4 minutes. In some preferred embodiments, the dwell time is from 4 to 6 minutes. In some preferred embodiments, the dwell time is from 6 to 8 minutes. In some preferred embodiments, the dwell time is from 8 to 10 minutes. In some preferred embodiments the dwell time is from 5 to 10 minutes. In some preferred embodiments, the dwell time is greater than 10 minutes.
[0037] In some preferred embodiments the RBS delivers radiation to an irradiated area, e.g., having a diameter. In some preferred embodiments, the diameter of the irradiated area is up to 6 millimeters. In some preferred embodiments, the diameter of the irradiated area is up to 8 millimeters. In some preferred embodiments, the diameter of the irradiated area is up to 10
millimeters. In some preferred embodiments, the diameter of the irradiated area is up to 12 millimeters. In some preferred embodiments, the diameter of the irradiated area is 3-5 millimeters. The present invention is not limited to the aforementioned diameters.
[0038] In some preferred embodiments, the RBS is a source of ionizing radiation. In some preferred embodiments, the RBS is a source of particle radiation. In some preferred embodiments, the RBS is a source of beta radiation. In some preferred embodiments, the RBS is a source of X-ray radiation. In some preferred embodiments, the RBS is a source of multiple types of radiation.
[0039] In some preferred embodiments, the RBS is contained within a cannula. In some preferred embodiments the cannula is part of a delivery device. In some preferred embodiments, the delivery device comprises: a cannula comprising a curved distal portion adapted for placement around a portion of a globe of an eye; a curved proximal portion, the curved distal portion and the curved proximal portions being connected with each other at an inflection point where the direction of the curvature changes sign; and a straight proximal portion. In some preferred embodiments, the distal portion has a radius of curvature between about 9 mm to 15 mm and an arc length between about 25 mm to 35 mm; and the proximal portion has a radius of curvature between about an inner cross-sectional radius of the cannula and about 1 meter; and an angle 0i between a line [ 3 tangent to the distal portion and to the curved proximal portion at the inflection point and the straight proximal portion is between greater than about 0 degrees to about 180 degrees. The present invention is not limited to the aforementioned delivery device or cannula.
[0040] The present invention features a method of reducing hyperpermeability of large choroidal vessels in an eye of a patient in need thereof with central serous chorioretinopathy. In some
preferred embodiments, the method comprises inserting a cannula into a potential space under a Tenon' s capsule of the eye of the patient, the cannula having a radionuclide brachytherapy source (RBS) at a treatment position, whereby the RBS is positioned over a choroid target, and wherein a therapeutic dose of radiation is delivered to the choroid target.
[0041] The present invention features a method of increasing collagen deposition associated with large choroidal vessels in an eye of a patient in need thereof with central serous chorioretinopathy. In some preferred embodiments, the method comprises inserting a cannula into a potential space under a Tenon' s capsule of the eye of the patient, the cannula having a radionuclide brachytherapy source (RBS) at a treatment position, whereby the RBS is positioned over a choroid target, and wherein a therapeutic dose of radiation is delivered to the choroid target. [0042] The present invention features a method of treating central serous chorioretinopathy in a patient in need thereof. In some preferred embodiments, the method comprises inserting a cannula into a potential space under a Tenon' s capsule of an eye of the patient, the cannula having a radionuclide brachytherapy source (RBS) at a treatment position, whereby the RBS is positioned over a choroid target, and wherein a therapeutic dose of radiation is delivered to the choroid target.
[0043] Referring to the aforementioned methods, in some preferred embodiments, the therapeutic dose is from 6 to 18 Gy. In some preferred embodiments the therapeutic dose is 6-8 Gy. In some preferred embodiments the therapeutic dose is 6-10 Gy. In some preferred embodiments the therapeutic dose is 6-12 Gy. In some preferred embodiments the therapeutic dose is 6-16 Gy. In some preferred embodiments the therapeutic dose is 8-10 Gy. In some preferred embodiments the therapeutic dose is 8-12 Gy. In some preferred embodiments the therapeutic dose is 8-16 Gy. In some
preferred embodiments the therapeutic dose is 8-18 Gy. In some preferred embodiments the therapeutic dose is 10-12 Gy. In some preferred embodiments the therapeutic dose is 10-14 Gy. In some preferred embodiments the therapeutic dose is 10-18 Gy. In some preferred embodiments the therapeutic dose is 12-16 Gy. In some preferred embodiments the therapeutic dose is 12-18 Gy. In some preferred embodiments the therapeutic dose : s 14-18 Gy.
[0044] In some pre: erred embodiments, th« retina is exposed to less than 8 Gy. In some preferred embodiments, a choriocapillaris is exposed to less than 10 Gy.
[0045] In some preferred embodiments, an interface of large choroidal vessels and a choriocapillaris is exposed to less than 12 Gy. In some preferred embodiments, a retina is exposed to less radiation than the choroid target. In some preferred embodiments, a choriocapillaris is exposed to less radiation than the choroid target .
[0046] As will be described herein, in some preferred embodiments, the therapeutic dose is fractionated over multiple sessions. For example, the therapeutic dose may be fractionated over at least two sessions.
[0047] The dose is delivered to the choroid target in a period of time, e.g. , a dwell time. In some preferred embodiments, the dwell time is from 5 seconds to 10 minutes. In some preferred embodiments, the dwell time is from 5 seconds to 15 second. In some preferred embodiments, the dwell time is from 5 seconds to 30 seconds. In some preferred embodiments, the dwell time is from 5 seconds to 45 seconds. In some preferred embodiments, the dwell time is from 5 seconds to 1 minute. In some preferred embodiments, the dwell time is from 5 seconds to 2 minutes. In some preferred embodiments, the dwell time is from 15 seconds to 30 seconds. In some preferred embodiments, the dwell time is from 15 seconds to 1 minute. In some preferred embodiments, the dwell time is from 15
seconds to 90 seconds. In some preferred embodiments, the dwell time is from 15 seconds to 2 minutes. In some preferred embodiments, the dwell time is from 30 seconds to 1 minute. In some preferred embodiments, the dwell time is from 1 minute to 90 seconds. In some preferred embodiments, the dwell time is from 1 minute to 2 minutes. In some preferred embodiments, the dwell time is from 90 seconds to 2 minutes. In some preferred embodiments, the dwell time is from 2 to 4 minutes. In some preferred embodiments, the dwell time is from 4 to 6 minutes. In some preferred embodiments, the dwell time is from 6 to 8 minutes. In some preferred embodiments, the dwell time is from 8 to 10 minutes. In some preferred embodiments the dwell time is from 5 to 10 minutes. In some preferred embodiments, the dwell time is greater than 10 minutes.
[0048] In some preferred embodiments, the RBS delivers radiation to a treatment area, wherein a diameter of the treatment area is up to 8 millimeters. In some preferred embodiments, the RBS is a source of ionizing radiation. In some preferred embodiments, the RBS is a source of beta radiation. In some preferred embodiments, the RBS is a source of X-ray radiation. In some preferred embodiments, the RBS is a source of multiple types of radiation.
[0049] In some preferred embodiments, the RBS is contained within a cannula. In some preferred embodiments the cannula is part of a delivery device. In some preferred embodiments, the delivery device comprises: a cannula comprising a curved distal portion adapted for placement around a portion of a globe of an eye; a curved proximal portion, the curved distal portion and the curved proximal portions being connected with each other at an inflection point where the direction of the curvature changes sign; and a straight proximal portion. In some preferred embodiments, the distal portion has a radius of curvature between about 9 mm to
15 mm and an arc length between about 25 mm to 35 mm; and the proximal portion has a radius of curvature between about an inner cross-sectional radius of the cannula and about 1 meter; and an angle 01 between a line 13 tangent to the distal portion and to the curved proximal portion at the inflection point and the straight proximal portion is between greater than about 0 degrees to about 180 degrees. The present invention is not limited to the aforementioned delivery device or cannula.
[0050] In some preferred embodiments, the dose delivered is such that radiation retinopathy is avoided. In some preferred embodiments, the dose delivered is such that radiation choroidopathy is avoided. In some preferred embodiments, the dose delivered is such that radiation maculopathy is avoided. In some preferred embodiments, the dose delivered is such that radiation neuropathy is avoided. In some preferred embodiments, the dose delivered is such that cataract is avoided. In some preferred embodiments, the dose delivered is such that choroidal neovascularization is avoided.
[0051] One of the unique and inventive technical features of the present invention is the ability to provide a therapeutically effective dose to the choroid target while avoiding or minimizing damage to other structures of the eye, for example the retina and choriocapillaris . Without wishing to limit the invention to any theory or mechanism, it is believed that the technical feature of the present invention advantageously provides for treatment efficacy while avoiding or minimizing adverse effects of treatment, for example the development of radiation retinopathy, radiation choroidopathy, radiation maculopathy, radiation neuropathy, cataract, and/or choroidal neovascularization. None of the presently known prior references or work has the unique inventive technical feature of the present invention.
[0052] The present invention represents an unexpected
advancement in the field of brachytherapy. As will be described herein, prior uses of brachytherapy, and radiotherapy more generally, have taught away from the use of brachytherapy for the treatment of CSCR as implemented in the present invention.
[0053] Radiotherapy (and brachytherapy, as a subfield of radiotherapy) has conventionally been believed to increase , rather than decrease, vascular permeability. Thus, the fact that the present invention decreases vascular permeability through the use of radiation is a surprising result. Radiation has for many decades been taught as increasing vascular permeability: "Research in the 1940' s and 50' s suggested that multiple mechanisms were responsible for increased endothelial barrier permeability following radiation exposure." (Bouten et al. , (2021) Tissue Barriers in Disease, Injury and Regeneration (pp. 43-94) . Elsevier) . Furthermore, radiation exposure has been taught by the prior art to "destabiliz [e] [the] endothelial barrier, increasing vascular permeability, and altering vesicular trafficking." (Bouten et al. , 2021) . These effects of radiation have been observed in vivo in "a wide variety of animal models" and in vitro. (Bouten et al. , 2021) . In in vivo rabbit models, radiation has been taught as increasing "capillary permeabilization" in a localized manner. (Bouten et . al, 2021) .
[0054] Furthermore, this phenomenon has previously been believed to apply to multiple types of radiation at multiple levels of intensity, exposure, or dose. " [C] comparisons of different types of radiation suggest that there is consistency in the effects of radiation on vasculature in response, towards increased vascular permeability, to different energies." (Bouten et al. 2021)
[0055] Furthermore, the relationship between radiation exposure and increased vascular permeability has been reported even at relatively low levels of radiation exposure. "Several studies have
demonstrated that vascular permeability increases immediately after irradiation with doses as low as 2 Gy" (Lee, C. G. , et al. (2021) , Journal of Radiation Research, 62 (5) , 856-860) . Therefore, the fact that even the low and controlled radiation doses delivered by the present invention do not increase vascular permeability, but rather decrease it, is nevertheless unexpected. In other words, that the present invention uses radiation (even at low doses) to decrease vascular permeability is an unexpected and surprising result not taught by the prior art. In fact, the prior art teaches away from using even low doses of radiation to decrease vascular permeability, since the prior art teaches that even low doses of radiation increase vascular permeability. In contrast, the present invention surprisingly produces a reduction in vascular permeability via the use of low and well-controlled doses of radiation .
[0056] More recent research has illuminated the molecular mechanisms that underlie the general tendency of radiation to increase vascular permeability. "A common finding from radiation in vitro studies of the endothelial barrier is the reduction in levels of proteins required for endothelial cell-cell contacts." (Bouten et al. , 2021) "Our results suggest a mechanism of irradiation-induced increased permeability... based on the activation of ADAM10 and the subsequent change of endothelial permeability through the degradation and internalization of VE- cadherin . " (Kouam, P. N. , et al. (2019) . BMC Cancer, 19 (1) , 958) . Furthermore, research has identified that radiation levels even as low as 5 Gy gamma radiation or photon-based radiation induces reduction of PECAM-1, an endothelial cell adhesion molecule that is required for endothelial cell-cell adhesion. (Bouten et al. , 2021) Other research found that "vascular permeability increases immediately after irradiation with doses as low as 2 Gy." (Lee et al. , 2021)
[0057] Human blood vessels have been found to exhibit increased permeability after exposure of the endothelial layer to ionizing radiation. Furthermore, this relationship has been found to apply to macromolecules of varying sizes, and to be dose-dependent. This has been correlated with decreased amounts of two junction proteins, one of which was VE-cadherin. VE-cadherin was cleaved by ADAM10 in a radiation dose-dependent manner, which appears to be mediated at least in part by intracellular calcium release. Inhibition of ADAMIO rescued radiation-induced permeability (Kabacik, S. et al. (2017) . Oncotarget, 8 (47) , 82049-82063) .
[0058] Further research has identified "at least two mechanisms" that cause "radiation-induced endothelial permeability," " (1) the regulation of levels of cell-cell contact proteins and (2) the increased contractility of endothelial cells" (Bouten et al. , 2021) . Other mechanisms of radiation-induced permeability changes may be due to due to changes in non- paracellular routes, including changes to: osmotically-based passive transporters (e.g., decreased expression of aquaporin 1) , tissue plasminogen activator (which converts plasminogen to plasmin, which in turn breaks down blood clots) , and vascular cell adhesion protein 1 (VCAM1, a protein involved in leukocyte extravasation) . In general, these alterations constitute changes in gene expression that typically involve "reduced adhesion and altered molecule transport." (Bouten et al., 2021)
[0059] The clinical use of coronary brachytherapy directly teaches away from the use of brachytherapy as used in the present invention. Coronary brachytherapy is used in conjunction with coronary angioplasty, and operates on the principle that, in short, radiation delivered to a blood vessel will prevent thickening of the vessel' s wall.
[0060] Atherosclerosis is the formation of fatty plaques in the lumen of arteries, which reduces the area of the lumen, inhibiting
blood flow and oxygen delivery to tissues (Nath, R. , et al. (1999) , Med. Phys. , 26: 119-152) . Plaque formation eventually causes smooth muscle cell proliferation, accompanied by collagen and elastin proliferation. In turn, fibrous plaques begin to form which contain lipids, necrotic cells, and collagen. These lesions calcify, causing platelet aggregation, a reduction in blood flow, and formation of a thrombosis, which, particularly if located in the heart, may cause myocardial ischemia or myocardial infarction. (Nath, R., et al. (1999) ) [0061] Percutaneous transluminal angioplasty ("angioplasty") is a procedure intended to break up these plaques, therefore restoring blood flow and preventing myocardial ischemia and/or myocardial infarction. The primary goal of angioplasty is to reestablish a stable lumen with a diameter similar to a normal, healthy artery. Angioplasty is a practice well-known in the art that can be accomplished using a variety of devices and techniques. Described herein in gross detail as an exemplary form of angioplasty is balloon angioplasty. A catheter on a guidewire is introduced into an artery (typically the femoral artery or brachial artery) , and advanced with the aid of imaging to the target artery, usually a coronary artery. The angioplasty device (for example, a balloon angioplasty device) is then inserted and guided via the guidewire to the site of the target lesion to be treated. The angioplasty device (e.g., a balloon angioplasty device) is then used to treat the target lesion by, for example, inflating the balloon within the arterial lumen. Use of the device (e.g. , inflation of the balloon) is intended to increase the diameter of the artery and break up plaques in the target lesion. Physical inflation of the balloon breaks up plaques, and stretches (and often ruptures) the tissues of the vessel lumen, typically the internal elastic lamina. Tissue fissures may extend into the medial layer of the vessel. (Nath, R. , et al. (1999) )
[0062] Following the angioplasty procedure, restenosis (e.g. , re-narrowing) of the vessel is a common and therapeutically undesirable occurrence. Restenosis is believed to involve three separate mechanisms: early recoil, neointimal hyperplasia, and late contraction. Early recoil is simply the elastic recoil that occurs after overstretching of the artery due to stretching produced by the angioplasty procedure itself (e.g. , as caused by inflation of an angioplasty balloon within the arterial lumen) . Intimal proliferation is the result of new tissue growth which proliferates to fill in fissures in the vessel wall produced by the stretching trauma of the angioplasty procedure. Often, this tissue proliferation may occur to the extent that the vessel is severely re-obstructed. Late contraction resembles wound contracture, and is sometimes referred to as remodeling. It essentially involves healed tissues becoming contracted such that the circumference of the vessel is smaller after the procedure than it was before the procedure.
[0063] Intimal hyperplasia (the second mechanism of restenosis) is particularly problematic, with excessive neointimal hyperplasia causing clinically symptomatic restenosis in three to six months in roughly 40% of patients. (Nath, R., et al. (1999) )
[0064] Thus, there exists a strong need to minimize intimal hyperplasia following angioplasty. This is the primary goal of coronary brachytherapy. Following angioplasty, radioactive sources, often beta or gamma emitters, are introduced inside the vessel and used to irradiate the treatment site. (Nath, R. , et al. (1999) ) Studies, both clinical and those in animal models, have confirmed that coronary brachytherapy decreases neointimal hyperplasia following angioplasty. (Nath, R., et al. (1999) ) This discovery followed the hypothesis that "intracoronary irradiation may reduce vascular smooth muscle proliferation and neointimal proliferation after a balloon overstretch procedure, which could
prevent or reduce in-stent restenosis." (Ohri, N. , et al. (2015) . Advances in radiation oncology, 1 (1) , 4-9) Indeed, studies in porcine models found that "intracoronary radiation primarily inhibits the first wave of cell proliferation in the vessel wall and demonstrates a favorable effect on late remodeling by preventing adventitial fibrosis at the injury site." (Waksman, R. , et al. (1997) . Circulation, 96 (6) , 1944-1952.
[0065] Conversely, the present invention uses radiation to increase proliferation of certain cells in blood vessel walls, thereby decreasing the permeability of those vessels. This is in contrast to the prior art, which teaches that radiation, even at low doses, decreases cellular proliferation, including by decreasing proliferation of cells in vessel walls (e.g. , including by decreasing intimal hyperplasia) .
[0066] In contrast to this established understanding of radiation' s effects on cellular proliferation, the present invention utilizes radiation to increase cellular proliferation of cells in choroidal vessel walls, thus decreasing the permeability of these vessels. Choroidal vessels in a patient with chronic serous chorioretinopathy are thereby made less permeable, reducing the amount of fluid they leak. As a result, less fluid accumulates under the retina, which resolves the underlying pathophysiological cause of CSCR, thus treating CSCR by stopping the disease process which causes it.
[0067] Without wishing to limit the present invention to any theory or mechanism, it is believed that an advantage of the present invention over previous approaches is that the present invention is capable of increasing intimal proliferation of large choroidal vessels while simultaneously minimizing damage to smaller blood vessels, especially those of the choriocapillaris . Other approaches have shown to cause damage to smaller, more delicate vessels, perhaps most importantly those of the
choriocapillaris . Attenuation of the choriocapillaris is often an inherent part of the pathophysiological process of CSCR. Therefore, while it is always desirable to avoid unnecessary damage to the choriocapillaris, doing so is especially important in CSCR, given that the choriocapillaris is often compromised by the disease state itself.
[0068] Smaller vessels are often more sensitive to radiation than larger vessels. For example, studies by Amoaku et al. studied the effects of brachytherapy on choroidal vasculature in the treatment of choroidal melanoma, and found that the among the vessels which experienced radiation-induced atrophy first were vessels of the choriocapillaris. (Amoaku, W. M. K. , et al. (1995) . Eye, 9 (6) , 738-744) Initial changes centered around smaller vessels, with larger vessels experiencing changes later on. Because treatment of CSCR may involve the goal of decreasing the permeability of large choroidal vessels without obliterating the smaller vessels of the choriocapillaris, radiotherapy as previously known in the art would have represented challenges if used for the treatment of CSCR.
[0069] However, the present invention resolves this issue by allowing for the delivery of radiotherapy to the eye such that intimal proliferation of large choroidal vessels is increased, thereby decreasing their permeability, while minimizing damage to the smaller vessels of the choriocapillaris or the retina. In some preferred embodiments, this is accomplished in part by the delivery of an appropriate dose. In some preferred embodiments, the therapeutic dose is from 6 to 18 Gy. As will be described herein, the present invention is not limited to 6 to 18 Gy. Without wishing to limit the present invention to any theory or mechanism, it is believed that the doses in these ranges are such that intimal proliferation of large choroidal vessels is increased while minimizing damages to vessels of the choriocapillaris and other
radiosensitive structures of the eye, such as the lens.
[0070] In some preferred embodiments, the present invention features the use of specialized delivery devices such as but not limited to those described in US Patent Application No: 10/836, 140; US Patent Application No: 12/350, 079; US Patent Application No: 12/497, 644; US Patent Application No: 13/111, 765; US Patent Application No: 13/111, 780; US Patent Application No: 13/742, 823; US Patent Application No: 13/872, 941; US Patent Application No: 13/953, 528; US Patent Application No: 14/011, 516; US Patent Application No: 14/486, 401; US Patent Application No: 14/687,784; US Patent Application No: 15/871, 756; US Patent Application No: 15/023, 196; US Patent Application No: 15/004, 538; US Patent Application No: 15/628, 952; US Patent Application No: 16/015, 892; US Patent Application No: 16/009, 646; U.S. Design Application No. 29/332, 021; U.S. Design Application No. 29/332, 028; U.S. Design Application No. 29/332, 032; U.S. Design Application No. 29/332, 040; U.S. Design Application No. 29/368, 499; U.S. Design Application No. 29/368, 501; U.S. Design Application No. 29/391, 557; U.S. Design Application No. 29/391, 558; U.S. Design Application No. 29/391, 559; U.S. Design Application No. 29/391, 561; U.S. Design Application No. 29/564,244; U.S. Design Application No. 29/564,247; U.S. Design Application No. 29/564,249; U.S. Design Application No. 29/576, 148; U.S. Design Application No. 29/576, 159; PCT Application No: PCT/US2009 / 030343 ; PCT Application No: PCT/US2010 / 54958 ; PCT Application No: PCT/US2014 / 56135 ; PCT Application No: PCT/US2016 / 68391 , the specifications of which are incorporated herein in their entirety by reference. Using a specialized device can allow for delivery of an accurate and appropriate dose to a well-defined target area of the eye. In some preferred embodiments, the present invention may therefore minimize the risk associated with any one or more of the following adverse effects associated with radiotherapy:
radiation retinopathy, radiation choroidopathy, radiation maculopathy, radiation neuropathy, cataract, and choroidal neovascularization. In some preferred embodiments the present invention may minimize the risk associated with other adverse effects associated with radiotherapy, especially those associated with delivery of excessive doses of radiation.
[0071] Any feature or combination of features described herein are included within the scope of the present invention provided that the features included in any such combination are not mutually inconsistent as will be apparent from the context, this specification, and the knowledge of one of ordinary skill in the art. Additional advantages and aspects of the present invention are apparent in the following detailed description and claims.
[0072] The above and other elements, features, steps, characteristics and advantages of the present invention will become more apparent from the following detailed description of the preferred embodiments with reference to the attached drawings.
BRIEF DESCRIPTION OF THE DRAWINGS
[0073] The features and advantages of preferred embodiments of the present invention will become apparent from a consideration of the following detailed description presented in connection with the accompanying drawings in which:
[0074] FIG. 1 shows a depiction of exponential decline in radiation dose with depth from the device. Graph showing exponential decline of the dose of radiation with increasing depth from the device.
[0075] FIG. 2 shows doses of radiation delivered at different depths from the scleral surface (device-sclera interface) . Dose = Dn exp[- 0.846 (d- dn) ] , where the depth of interest is d. Dn is the dose at the depth dn which is the normalization depth (or treatment depth)
[0076] FIG. 3 shows that in a normal eye, the dose of radiation delivered at the sclera-choroid interface is 12.4 Gy. The dose is 10 Gy at the interface of large choroidal vessels and medium vessels/ chor iocapillar is .
[0077] FIG. 4 shows that in an eye with central serous chorioretinopathy (CSCR) , the dose of radiation delivered at the sclera-choroid interface would be less than 12.4 Gy, considering the increased scleral thickness in CSCR. The dose of radiation at the interface of large choroidal vessels and medium vessels/choriocapillaris will be 8 Gy because of the increased thickness of the large choroidal vessels layer.
[0078] FIG. 5 shows an episcleral brachytherapy device introduced via sub-Tenon route to deliver radiation to a choroidal neovascular complex through the sclera.
[0079] FIG. 6 shows a non-limiting example of a cannula/delivery device.
[0080] FIG. 7A shows a non-limiting example of a cannula/delivery device.
[0081] FIG. 7B shows a detailed view of the radius of curvature of a portion of a cannula.
[0082] FIG. 7C shows a detailed view of the radius of curvature of a portion of a cannula.
[0083] FIG. 7D shows a detailed view of the relationship between the straight portion of the cannula and the distal and proximal portions of a cannula.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0084] The present invention features radionuclide brachytherapy sources (RBS) for applying radiation to a target area, for example for treating chronic serous chorioretinopathy (CSCR) .
Brachytherapy for Central Serous Chorioretinopathy
[0085] The present invention may be used to provide low dose radiation via episcleral brachytherapy in refractory cases of central serous chorioretinopathy (CSCR) .
[0086] The pathogenesis of CSCR involves dilatation and hyperpermeability of large choroidal vessels. Low dose radiation can induce intimal proliferation in large choroidal vessels and decrease their hyperpermeability. Concerns about the use of brachytherapy in CSCR include damage to the choriocapillaris or the retinal vessels. This can be addressed with the use of a specialized device through which a very precise and appropriate dose can be delivered. The dose of the radiation delivered decreases exponentially at a depth of approximately 0.5-1.5 mm from the device-sclera interface.
[0087] Dose titration of the radiation is key to minimize the damage to the choriocapillaris and avoid radiation retinopathy, radiation maculopathy, radiation neuropathy, and cataract. Specialized devices for episcleral brachytherapy such as the SalutarisMD promise additional safety and ease of performing the procedure, thus making it more practical.
[0088] Central serous chorioretinopathy (CSCR) is a disease characterized by the neurosensory detachment with or without pigment epithelial detachment due to dysfunctional retinal pigment epithelium (RPE) and hyperpermeable choroid. Choroidal features of CSCR are choriocapillaris attenuation and dilatation of large vessels of the choroid. Whether dilated large vessels of the choroid cause a mechanical compression of the choriocapillaris layer, or atrophy of the choriocapillaris is the primary event, is still debatable.
[0089] The acute, isolated event of CSCR mostly resolves spontaneously, but the chronic variant of the disease, which is also known as diffuse retinal pigment epitheliopathy , is
progressive and can lead to severe bilateral visual impairment. Many treatment options have been tried for this form of the disease and so far photodynamic therapy (PDT) is the treatment of choice. However, PDT shows limited success in 30-40% of cases with risk of complications including vision loss. Limited availability of verteporfin and laser systems in many countries and an off-label indication are making PDT as a vanishing treatment option. The limited role of eplerenone, as reported by the VICI trial, further limits the treatment options for this debilitating disease.
[0090] The prime target of the present invention is the hyperpermeable choroidal vasculature. Concerns associated with plaque radiotherapy include platelet aggregates, development of choroidal neovascularization (CNV) , radiation maculopathy, optic neuropathy, and radiation chorioretinopathy.
[0091] Radionuclide strontium-90 (90Sr) emits only high energy beta particles which have highest attenuation in biological tissues making it more suitable for ocular use. Yttrium-90 (90Y) is the daughter product of 90Sr after beta decay and emits more energetic beta particles.
[0092] Stereotactic radiotherapy is another method of radiotherapy that provides stereotactic application of low energy X-ray to the CNV using three highly collimated beams that cross the inferior sclera to overlap at the macula. Unlike epimacular brachytherapy, this outpatient-based radiotherapy does not require vitrectomy and thus is a more practical method of radiotherapy. [0093] An aim of the present invention is to decrease the blood flow through the large choroidal vessels without obliteration of the choriocapillaris . The mechanism of action in this case would likely be due to the effect of radiation on the endothelial cells. The radiation dose can even be reduced further to attain the desired effect of producing intimal proliferation whereby the leakiness stops or is reduced. Unlike the effect on cancer cells
where the objective is to create enough deoxyribonucleic acid (DNA) double-strand breaks to induce cell death, in its application for CSCR, the lower radiation dose will cause deposition of collagen around the leaky vessels thus changing their permeability over a period of months.
[0094] When an RBS is placed on or near the sclera, it may be possible for the radiation to affect the large choroidal vessel layer without adversely affecting the choriocapillaris . Referring to FIG. 1, FIG. 2, FIG. 3, and FIG. 4, the dose of the radiation is an exponential function for depths from approximately 0.5 mm to 1.5 mm, where the depth is measured from the front face of the device (the device-sclera interface has a depth of zero) . Dose = Dn exp[- 0.846 (d-dn) ] , where the depth of interest is d. Dn is the dose at the depth dn which is the normalization depth (or treatment depth) . Studies have shown choroidal thickness at the macula is around 256 Im of which 2041m is occupied by the large vessels (Haller layer) and 521m by the choriocapillaris/Satt ler layer in normal eyes. In CSCR, total choroidal thickness is increased (394 pm) because of increased thickness of the large vessel layer (307 pm) . Scleral thickness at the posterior pole is around 1 mm. Although scleral thickness at the posterior pole has not been measured in eyes with CSCR, scleral thickness 6 mm posterior to the scleral spur, as measured on anterior segment optical coherence tomography, is thicker than in normal eyes and an increased scleral thickness has been implicated in the pathogenesis of CSCR.
[0095] The typical human choroid is generally between 0.5 mm to 1.5 mm deep in the structure of the eye, as measured from the posterior surface of the eye. The target is the choroid, e.g. , the approximate median depth of the choroid. The present invention describes delivering a therapeutic dose to a particular range of depths (as measured from the interface of the sclera and delivery device) . In some preferred embodiments, the depth ranges from 0.5
mm to 2.0 mm. In some preferred embodiments, the depth ranges from 0.75 mm to 2.0 mm. In some preferred embodiments, the depth ranges from 1.0 mm to 2.0 mm. In some preferred embodiments, the depth ranges from 0.5 mm to 1.5 mm. The present invention is not limited to the aforementioned depth ranges relevant to the therapeutic dose delivery.
[0096] The choroid is within the range of depths to which the therapeutic dose (s) is delivered, e.g. , in some preferred embodiments, the depth of the target (e.g. , median depth of the choroid) is 1.25 mm from the interface of the sclera and delivery device, therefore the target receives the therapeutic dose. In some preferred embodiments, the choroid target is from 0.5 to 2 mm from the interface of the sclera and delivery device. In some preferred embodiments, the choroid target is from 0.75 to 1.5 mm from the interface of the sclera and delivery device. In some preferred embodiments, the choroid target is from 0.5 to 2 mm from the interface of the sclera and delivery device. In some preferred embodiments, the choroid target is from 1 to 1.5 mm from the interface of the sclera and delivery device. In some preferred embodiments, the choroid target is from 0.75 to 1.75 mm from the interface of the sclera and delivery device.
[0097] A radiation dose delivered to the choriocapillaris of less than 10 Gy may induce intimal proliferation in larger choroidal vessels, thus reducing hyperpermeability of these vessels, while also minimizing damage to the choriocapillaris and other more radiosensitive structures of the eye.
[0098] A novel episcleral brachytherapy device has been introduced by Salutaris Medical Devices, Inc. (SalutarisMD) to treat wet AMD with an accurate therapeutic dose. It employs a 90Sr/90Y source RBS encapsulated in a stainless steel holder which is loaded into the distal end of the applicator' s curved cannula. The device is introduced through the retrobulbar sub-Tenon route
and radiation is delivered through the sclera to the CNV lesion over a matter of minutes (see FIG. 5) . A clinical trial to assess the safety and feasibility of the device in patients with wet AMD has been started and is expected to complete in 2022.
[0099] Dose titration of the radiation is key to minimize the damage to the choriocapillaris and other radiosensitive structures of the eye, and to avoid radiation retinopathy, radiation maculopathy, radiation neuropathy, and cataract. Specialized devices for episcleral brachytherapy such as the SalutarisMD may be used in conjunction with the present invention in order to provide additional safety and ease of performing a procedure utilizing the present invention, thus making it more practical.
RBS systems for Chronic Serous Chorioretinopathy
[0100] The present invention may be used to treat chronic serous chorioretinopathy (CSCR) . For example, the present invention features a radionuclide brachytherapy source (RBS) for use in a method of irradiating a target of an eye, the method comprising inserting said cannula into a potential space under a Tenon' s capsule of the eye, whereby the RBS is positioned over a choroid target at the back of the eye, wherein a therapeutic dose of radiation is delivered to the choroid target. A radioactive therapeutic portion of the RBS is consumed during the method. The RBS may be present in a delivery device, e.g. , in a cannula of a delivery device.
[0101] As previously discussed, in some preferred embodiment, the choroid target is from 0.5 to 2 mm from the interface of the sclera and delivery device. In some preferred embodiments, the choroid target is from 0.75 to 1.5 mm from the interface of the sclera and delivery device. In some preferred embodiments, the choroid target is from 0.5 to 2 mm from the interface of the sclera and delivery device. In some preferred embodiments, the choroid
target is from 1 to 1.5 mm from the interface of the sclera and delivery device. In some preferred embodiments, the choroid target is from 0.75 to 1.75 mm from the interface of the sclera and delivery device.
[0102] Without wishing to limit the present invention to any theory or mechanism, the therapeutic doses are generally selected such that intimal proliferation of large choroidal vessels is increased while damage to vessels of the choriocapillaris and other radiosensitive structures of the eye, such as the lens, are minimized. In general, it is desirable to avoid excessive radiation exposure to structures other than the target (e.g. , large choroidal vessels) . Other radiosensitive structures that it may be desirable to avoid radiation exposure to include the lens, the choriocapillaris, the retina, and retinal blood vessels.
[0103] In some preferred embodiments, the therapeutic dose is from 6 to 18 Gy. In some preferred embodiments the therapeutic dose is 6-8 Gy. In some preferred embodiments the therapeutic dose is 6-10 Gy. In some preferred embodiments the therapeutic dose is 6-12 Gy. In some preferred embodiments the therapeutic dose is 6-
16 Gy. In some preferred embodiments the therapeutic dose is 8-10
Gy. In some preferred embodiments the therapeutic dose is 8-12 Gy.
In some preferred embodiments the therapeutic dose is 8-16 Gy. In some preferred embodiments the therapeutic dose is 8-18 Gy. In some preferred embodiments the therapeutic dose is 10-12 Gy. In some preferred embodiments the therapeutic dose is 10-14 Gy. In some preferred embodiments the therapeutic dose is 10-18 Gy . In some preferred embodiments the therapeutic dose is 12-16 Gy. In some preferred embodiments the therapeutic dose is 12-18 Gy. In some preferred embodiments the therapeutic dose is 14-18 Gy.
[0104] The therapeutic dose is delivered to a particular depth or range of depths, e.g. , as measured from the interface of the sclera and the delivery device. For example, in some preferred
embodiments, the therapeutic dose delivered to a depth from 0.5 mm to 2 mm is from 6-18 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 0.5 mm to 2 mm is from 6-16 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 0.5 mm to 2 mm is from 6-14 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 0.5 mm to 2 mm is from 6-12 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 0.5 mm to 2 mm is from 8-18 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 0.5 mm to 2 mm is from 8-16 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 0.5 mm to 2 mm is from 8-14 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 0.5 mm to 2 mm is from 8-12 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 0.75 mm to 1.75 mm is from 6-18 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 0.75 mm to 1.75 mm is from 6-16 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 0.75 mm to 1.75 mm is from 6-14 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 0.75 mm to 1.75 mm is from 6-12 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 0.75 mm to 1.75 mm is from 8-18 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 0.75 mm to 1.75 mm is from 8-16 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 0.75 mm to 1.75 mm is from 8-14 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 0.75 mm to 1.75 mm is from 8-12 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 1 mm to 1.5 mm is from 6-18 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 1 mm to 1.5 mm is from 6-16 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 1 mm to 1.5 mm is
from 6-14 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 1 mm to 1.5 mm is from 6-12 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 1 mm to 1.5 mm is from 8-18 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 1 mm to 1.5 mm is from 8-16 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 1 mm to 1.5 mm is from 8-14 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 1 mm to 1.5 mm is from 8-12 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 0.5 mm to 1.25 mm is from 6-18 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 0.5 mm to 1.25 mm is from 6-16 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 0.5 mm to 1.25 mm is from 6-14 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 0.5 mm to 1.25 mm is from 6-12 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 0.5 mm to 1.25 mm is from 8-18 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 0.5 mm to 1.25 mm is from 8-16 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 0.5 mm to 1.25 mm is from 8-14 Gy. In some preferred embodiments, the therapeutic dose delivered to a depth from 0.5 mm to 1.25 mm is from 8-12 Gy.
[0105] In some preferred embodiments, the therapeutic dose is calculated based on the thickness of the choroid target. In some preferred embodiments, a thicker choroid target may dictate that a larger therapeutic dose is used. In some preferred embodiments, a thicker choroid target may dictate that a smaller therapeutic dose is used.
[0106] In some preferred embodiments, the thickness of the choroid target is measured using imaging. In some preferred embodiments, the imaging may comprise optical coherence tomography
(OCT) , optical coherence tomography (OCT) using enhanced depth imaging (EDI) , Spectral Domain Optical Coherence Tomography (SD- OCT) , Swept Source Optical Coherence Tomography (SS-OCT) , or Topcon Deep Range Imaging OCT.
[0107] In some preferred embodiments, the retina is exposed to less than 6 Gy. In some preferred embodiments, the retina is exposed to less than 8 Gy. In some preferred embodiments, a choriocapillaris is exposed to less than 8 Gy. In some preferred embodiments, a choriocapillaris is exposed to less than 10 Gy. In some preferred embodiments, an interface of large choroidal vessels and a choriocapillaris is exposed to less than 10 Gy. In some preferred embodiments, an interface of large choroidal vessels and a choriocapillaris is exposed to less than 12 Gy. In some preferred embodiments, the retina is exposed to less radiation than the choroid target. In some preferred embodiments, a choriocapillaris is exposed to less radiation than the choroid target. In some preferred embodiments, a lens is exposed to less radiation than the choroid target. In some preferred embodiments, a retinal blood vessel is exposed to less radiation than the choroid target .
[0108] The dose is delivered to the choroid target in a period of time, e.g. , a dwell time. In some preferred embodiments, the dwell time is from 5 seconds to 10 minutes. In some preferred embodiments, the dwell time is from 5 seconds to 15 second. In some preferred embodiments, the dwell time is from 5 seconds to 30 seconds. In some preferred embodiments, the dwell time is from 5 seconds to 45 seconds. In some preferred embodiments, the dwell time is from 5 seconds to 1 minute. In some preferred embodiments, the dwell time is from 5 seconds to 2 minutes. In some preferred embodiments, the dwell time is from 15 seconds to 30 seconds. In some preferred embodiments, the dwell time is from 15 seconds to 1 minute. In some preferred embodiments, the dwell time is from 15
seconds to 90 seconds. In some preferred embodiments, the dwell time is from 15 seconds to 2 minutes. In some preferred embodiments, the dwell time is from 30 seconds to 1 minute. In some preferred embodiments, the dwell time is from 1 minute to 90 seconds. In some preferred embodiments, the dwell time is from 1 minute to 2 minutes. In some preferred embodiments, the dwell time is from 90 seconds to 2 minutes. In some preferred embodiments, the dwell time is from 2 to 4 minutes. In some preferred embodiments, the dwell time is from 4 to 6 minutes. In some preferred embodiments, the dwell time is from 6 to 8 minutes. In some preferred embodiments, the dwell time is from 8 to 10 minutes. In some preferred embodiments the dwell time is from 5 to 10 minutes. In some preferred embodiments, the dwell time is greater than 10 minutes.
[0109] In some preferred embodiments the RBS delivers radiation to an irradiated area. In some preferred embodiments, the diameter of the irradiated area is up to 8 millimeters. In some preferred embodiments, the diameter of the irradiated area is up to 12 millimeters. In some preferred embodiments, the diameter of the irradiated area is 3-5 millimeters. In some preferred embodiments, the diameter of the irradiated area is 1-3 millimeters. In some preferred embodiments, the diameter of the irradiated area is 5-7 millimeters. In some preferred embodiments, the diameter of the irradiated area is 7-9 millimeters. In some preferred embodiments, the diameter of the irradiated area is 9-12 millimeters.
[0110] In some preferred embodiments, the RBS is a source of ionizing radiation. In some preferred embodiments, the RBS is a source of particle radiation. In some preferred embodiments, the RBS is a source of beta radiation. In some preferred embodiments, the RBS is a source of alpha radiation. In some preferred embodiments, the RBS is a source of neutron radiation. In some preferred embodiments, the RBS is a source of X-ray radiation. In
some preferred embodiments, the RBS is a source of other electromagnetic radiation. In some preferred embodiments, the RBS is a source of multiple types of radiation.
[0111] The present invention also features a method of reducing hyperpermeability of large choroidal vessels in an eye of a patient in need thereof with central serous chorioretinopathy. In some preferred embodiments, the method comprises inserting a cannula into a potential space under a Tenon' s capsule of the eye of the patient, the cannula having a radionuclide brachytherapy source (RBS) at a treatment position, whereby the RBS is positioned over a choroid target, and wherein a therapeutic dose of radiation is delivered to the choroid target. In some preferred embodiments, a reduction in hyperpermeability will result in less fluid accumulation under the retina, thus treating CSCR.
[0112] The present invention also features a method of increasing collagen deposition associated with large choroidal vessels in an eye of a patient in need thereof with central serous chorioretinopathy. In some preferred embodiments, the method comprises inserting a cannula into a potential space under a Tenon' s capsule of the eye of the patient, the cannula having a radionuclide brachytherapy source (RBS) at a treatment position, whereby the RBS is positioned over a choroid target, and wherein a therapeutic dose of radiation is delivered to the choroid target. In some preferred embodiments, an increase in collagen deposition associated with large choroidal vessels will cause a reduction in hyperpermeability that will result in less fluid accumulation under the retina, thus treating CSCR.
[0113] The present invention also features a method of treating central serous chorioretinopathy in a patient in need thereof. In some preferred embodiments, the method comprises inserting a cannula into a potential space under a Tenon' s capsule of an eye of the patient, the cannula having a radionuclide brachytherapy
source (RBS) at a treatment position, whereby the RBS is positioned over a choroid target, and wherein a therapeutic dose of radiation is delivered to the choroid target. In some preferred embodiments, treating CSCR may be accomplished by inducing a reduction in hyperpermeability of large choroidal vessels and/or increasing collagen deposition associated with large choroidal vessels and/or reducing fluid accumulation under the retina.
[0114] In some preferred embodiments, the dose delivered is such that radiation retinopathy is avoided. In some preferred embodiments, the dose delivered is such that radiation choroidopathy is avoided. In some preferred embodiments, the dose delivered is such that radiation maculopathy is avoided. In some preferred embodiments, the dose delivered is such that radiation neuropathy is avoided. In some preferred embodiments, the dose delivered is such that cataract is avoided. In some preferred embodiments, the dose delivered is such that choroidal neovascularization is avoided. In some preferred embodiments, the dose delivered is such that other adverse events of radiation therapy are avoided.
[0115] The therapeutic dose to be administered may be calculated a priori before any treatment course (or a portion thereof) is delivered.
[0116] Referring to the methods herein, the therapeutic dose to be administered, e.g. , a treatment course, may be fractionated (e.g., divided and delivered) over a number of sessions. For example, in some preferred embodiments, the therapeutic dose is fractionated over at least 2 sessions. In some preferred embodiments, the therapeutic dose is fractionated over 2 sessions. In some preferred embodiments, the therapeutic dose is fractionated over 3 sessions. In some preferred embodiments, the therapeutic dose is fractionated over 4 sessions. In some preferred embodiments, the therapeutic dose is fractionated over more than
4 sessions. In some preferred embodiments, the sessions are divided into a time frame of 1 week. In some preferred embodiments, the sessions are divided into a time frame of 2 weeks. In some preferred embodiments, the sessions are divided into a time frame of 3 weeks. In some preferred embodiments, the sessions are divided into a time frame of 4 weeks. In some preferred embodiments, the sessions are separated by 1 to 7 days. In some preferred embodiments, the sessions are separated by 5 to 10 days. In some preferred embodiments, the sessions are separated by 5 to 14 days. In some preferred embodiments, the sessions are separated by 5 to 21 days .
[0117] In some preferred embodiments, the patient is reassessed after a period of time following the first treatment course to determine if the patient needs a second treatment course. The patient may also be reassessed after additional treatment courses as well, for example, in some preferred embodiments, the patient is reassessed following a second treatment course to determine if the patient needs a third treatment course. In some preferred embodiments, the time frame between two particular treatment courses (e.g. , a first treatment course and a second treatment course, a second treatment course and a third treatment course, etc.) is 3-12 months. In some preferred embodiments, the time frame between two particular treatment courses is 3-6 months. In some preferred embodiments, the time frame between two particular treatment courses is 6 to 12 months. In some preferred embodiments, the time frame between two particular treatment courses is 3 to 24 months. In some preferred embodiments, the time frame between two particular treatment courses is 3 to 36 months. In some preferred embodiments, the time frame between two particular treatment courses is greater than a year. In some preferred embodiments, the time frame between two particular treatment courses is greater than 2 years. In some preferred embodiments, the time frame between
two particular treatment courses is greater than 3 years.
[0118] As described above, the first treatment course may be fractionated, e.g. , divided and delivered over the course of at least 2 sessions. Likewise, in some preferred embodiments, the second (or third or subsequent courses) may also be fractionated over at least 2 sessions.
[0119] In some preferred embodiments, the RBS is contained within a cannula. In some preferred embodiments the cannula is part of a delivery device, wherein the delivery device comprises: a cannula comprising a curved distal portion adapted for placement around a portion of a globe of an eye; a curved proximal portion, the curved distal portion and the curved proximal portions being connected with each other at an inflection point where the direction of the curvature changes sign; and a straight proximal portion, wherein (a) the distal portion has a radius of curvature between about 9 mm to 15 mm and an arc length between about 25 mm to 35 mm; and (b) the proximal portion has a radius of curvature between about an inner cross-sectional radius of the cannula and about 1 meter; and wherein an angle 91 between a line 13 tangent to the distal portion and to the curved proximal portion at the inflection point and the straight proximal portion is between greater than about 0 degrees to about 180 degrees. The present application incorporates the following patent applications in their entirety herein by reference: In some preferred embodiments, the present invention features the use of specialized delivery devices such as but not limited to those described in US Patent Application No: 10/836, 140; US Patent Application No: 12/350, 079; US Patent Application No: 12/497, 644; US Patent Application No: 13/111, 765; US Patent Application No: 13/111, 780; US Patent Application No: 13/742, 823; US Patent Application No: 13/872, 941; US Patent Application No: 13/953, 528; US Patent Application No: 14/011, 516; US Patent Application No: 14/486, 401; US Patent
Application No: 14/687, 784; US Patent Application No: 15/871,756; US Patent Application No: 15/023, 196; US Patent Application No: 15/004, 538; US Patent Application No: 15/628, 952; US Patent Application No: 16/015, 892; US Patent Application No: 16/009, 646; U.S. Design Application No. 29/332, 021; U.S. Design Application No. 29/332, 028; U.S. Design Application No. 29/332, 032; U.S. Design Application No. 29/332, 040; U.S. Design Application No. 29/368, 499; U.S. Design Application No. 29/368, 501; U.S. Design Application No. 29/391, 557; U.S. Design Application No. 29/391, 558; U.S. Design Application No. 29/391, 559; U.S. Design Application No. 29/391, 561; U.S. Design Application No. 29/564,244; U.S. Design Application No. 29/564,247; U.S. Design Application No. 29/564,249; U.S. Design Application No. 29/576, 148; U.S. Design Application No. 29/576, 159; PCT Application No: PCT/US2009/030343; PCT Application No: PCT/US2010/54958; PCT Application No: PCT/US2014/56135; PCT Application No: PCT/US2016 / 68391. FIG. 5, FIG. 6, FIG. 7A, FIG. 7B, FIG. 7C, and FIG. 7D show non-limiting examples of cannulas. For example, in some preferred embodiments, the system comprises a cannula (e.g. , as part of a delivery device) . In some preferred embodiments, the cannula (100) comprises a curved distal portion (110) adapted for placement around a portion of a globe of an eye; a curved proximal portion (120) , the curved distal portion and the curved proximal portions being connected with each other at an inflection point (130) where the direction of the curvature changes sign. In some preferred embodiments, the cannula comprises a straight proximal portion. In some preferred embodiments, the distal portion has a radius of curvature (180) between about 9 mm to 15 mm and an arc length between about 25 mm to 35 mm; and the proximal portion has a radius of curvature (190) between about an inner cross-sectional radius of the cannula and about 1 meter; and the angle 0i (425) between a line (420) tangent to the distal
portion and to the curved proximal portion at the inflection point and the straight proximal portion is between greater than about 0 degrees to about 180 degrees.
[0120] In some preferred embodiments, the present invention may be used to treat macular edema. In some preferred embodiments, the present invention features a radionuclide brachytherapy source (RBS) for use in a method of irradiating a target of an eye, wherein said RBS is present in a cannula of a delivery device, the method comprising inserting said cannula into a potential space under a Tenon' s capsule of the eye, whereby the RBS is positioned over a target at the back of the eye, wherein a therapeutic dose of radiation is delivered to the target, wherein a radioactive therapeutic portion of the RBS is consumed during the method. In some preferred embodiments, the therapeutic dose may range from 6 to 24 Gy. In some preferred embodiments, the target is a blood vessel. In some preferred embodiments, the target is located in the choroid. In some preferred embodiments, the target is located outside of the choroid.
[0121] In some preferred embodiments, the present invention may be used to treat diabetic retinopathy (DR) . In some preferred embodiments, the present invention features a radionuclide brachytherapy source (RBS) for use in a method of irradiating a target of an eye, wherein said RBS is present in a cannula of a delivery device, the method comprising inserting said cannula into a potential space under a Tenon' s capsule of the eye, whereby the RBS is positioned over a target at the back of the eye, wherein a therapeutic dose of radiation is delivered to the target, wherein a radioactive therapeutic portion of the RBS is consumed during the method. In some preferred embodiments, the therapeutic dose may range from 6 to 24 Gy. In some preferred embodiments, the target is a blood vessel. In some preferred embodiments, the target is located in the choroid. In some preferred embodiments, the
target is located outside of the choroid.
[0122] In some preferred embodiments, the present invention may be used to treat central macular edema (CME) . In some preferred embodiments, the present invention features a radionuclide brachytherapy source (RBS) for use in a method of irradiating a target of an eye, wherein said RBS is present in a cannula of a delivery device, the method comprising inserting said cannula into a potential space under a Tenon's capsule of the eye, whereby the RBS is positioned over a target at the back of the eye, wherein a therapeutic dose of radiation is delivered to the target, wherein a radioactive therapeutic portion of the RBS is consumed during the method. In some preferred embodiments, the therapeutic dose may range from 6 to 24 Gy. In some preferred embodiments, the target is a blood vessel. In some preferred embodiments, the target is located in the choroid. In some preferred embodiments, the target is located outside of the choroid.
[0123] In some preferred embodiments, the present invention may be used to treat macular edema (ME) secondary to central retinal vein occlusion (CRVO) . In some preferred embodiments, the present invention features a radionuclide brachytherapy source (RBS) for use in a method of irradiating a target of an eye, wherein said RBS is present in a cannula of a delivery device, the method comprising inserting said cannula into a potential space under a Tenon' s capsule of the eye, whereby the RBS is positioned over a target at the back of the eye, wherein a therapeutic dose of radiation is delivered to the target, wherein a radioactive therapeutic portion of the RBS is consumed during the method. In some preferred embodiments, the therapeutic dose may range from 6 to 24 Gy. In some preferred embodiments, the target is a blood vessel. In some preferred embodiments, the target is located in the choroid. In some preferred embodiments, the target is located outside of the choroid.
[0124] In some preferred embodiments, the present invention may be used to treat macular edema (ME) secondary to branch retinal vein occlusion (BRVO) . In some preferred embodiments, the present invention features a radionuclide brachytherapy source (RBS) for use in a method of irradiating a target of an eye, wherein said RBS is present in a cannula of a delivery device, the method comprising inserting said cannula into a potential space under a Tenon' s capsule of the eye, whereby the RBS is positioned over a target at the back of the eye, wherein a therapeutic dose of radiation is delivered to the target, wherein a radioactive therapeutic portion of the RBS is consumed during the method. In some preferred embodiments, the therapeutic dose may range from 6 to 24 Gy. In some preferred embodiments, the target is a blood vessel. In some preferred embodiments, the target is located in the choroid. In some preferred embodiments, the target is located outside of the choroid.
[0125] In some preferred embodiments, the present invention features a method of reducing hyperpermeability of large choroidal vessels in an eye of a patient in need thereof with at least one condition selected from the following: macular edema, diabetic retinopathy, diabetic macular edema, cystoid macular edema, macular edema secondary to central retinal vein occlusion, or macular edema secondary to branch retinal vein occlusion, said method comprising inserting a cannula into a potential space under a Tenon' s capsule of the eye of the patient, the cannula having a radionuclide brachytherapy source (RBS) at a treatment position, whereby the RBS is positioned over a target, and wherein a therapeutic dose of radiation is delivered to the target. In some preferred embodiments, the therapeutic dose may range from 6 to 24 Gy. In some preferred embodiments, the target is a blood vessel. In some preferred embodiments, the target is located in the choroid. In some preferred embodiments, the target is located
outside of the choroid.
[0126] In some preferred embodiments, the present invention features a method of increasing collagen deposition associated with large choroidal vessels in an eye of a patient in need thereof with at least one condition selected from the following: macular edema, diabetic retinopathy, diabetic macular edema, cystoid macular edema, macular edema secondary to central retinal vein occlusion, or macular edema secondary to branch retinal vein occlusion, said method comprising inserting a cannula into a potential space under a Tenon' s capsule of the eye of the patient, the cannula having a radionuclide brachytherapy source (RBS) at a treatment position, whereby the RBS is positioned over a target, and wherein a therapeutic dose of radiation is delivered to the target. In some preferred embodiments, the therapeutic dose may range from 6 to 24 Gy. In some preferred embodiments, the target is a blood vessel. In some preferred embodiments, the target is located in the choroid. In some preferred embodiments, the target is located outside of the choroid.
[0127] In some preferred embodiments, the present invention features a method of treating at least one condition selected from the following: macular edema, diabetic retinopathy, diabetic macular edema, cystoid macular edema, macular edema secondary to central retinal vein occlusion, or macular edema secondary to branch retinal vein occlusion in a patient in need thereof, said method comprising inserting a cannula into a potential space under a Tenon' s capsule of an eye of the patient, the cannula having a radionuclide brachytherapy source (RBS) at a treatment position, whereby the RBS is positioned over a target, and wherein a therapeutic dose of radiation is delivered to the target. In some preferred embodiments, the therapeutic dose may range from 6 to 24 Gy. In some preferred embodiments, the target is a blood vessel. In some preferred embodiments, the target is located in the
choroid. In some preferred embodiments, the target is located outside of the choroid.
[0128] Referring to the preferred embodiments herein, in some preferred embodiments, the dose delivered is such that radiation retinopathy is avoided. In some preferred embodiments, the dose delivered is such that radiation choroidopathy is avoided. In some preferred embodiments, the dose delivered is such that radiation maculopathy is avoided. In some preferred embodiments, the dose delivered is such that radiation neuropathy is avoided. In some preferred embodiments, the dose delivered is such that cataract is avoided. In some preferred embodiments, the dose delivered is such that choroidal neovascularization is avoided. In some preferred embodiments, the dose delivered is such that adverse effects are avoided.
[0129] As used herein, the term "about" refers to plus or minus 10% of the referenced number.
[0130] Although there has been shown and described the preferred embodiment of the present invention, it will be readily apparent to those skilled in the art that modifications may be made thereto which do not exceed the scope of the appended claims . Therefore, the scope of the invention is only to be limited by the following claims. In some preferred embodiments, the figures presented in this patent application are drawn to scale, including the angles, ratios of dimensions, etc. In some preferred embodiments, the figures are representative only and the claims are not limited by the dimensions of the figures. In some preferred embodiments, descriptions of the inventions described herein using the phrase "comprising" includes preferred embodiments that could be described as "consisting essentially of" or "consisting of", and as such the written description requirement for claiming one or more preferred embodiments of the present invention using the phrase "consisting essentially of" or "consisting of" is met.
[0131] The reference numbers recited in the below claims are solely for ease of examination of this patent application, and are exemplary, and are not intended in any way to limit the scope of the claims to the particular features having the corresponding reference numbers in the drawings.
Claims
1. A radionuclide brachytherapy source (RBS) for use in a method of irradiating a target of an eye, wherein said RBS is present in a cannula of a delivery device, the method comprising inserting said cannula into a potential space under a Tenon' s capsule of the eye, whereby the RBS is positioned over a target at the back of the eye, wherein a therapeutic dose of radiation is delivered to the target, wherein a radioactive therapeutic portion of the RBS is consumed during the method.
2. The RBS of claim 1, wherein the method of irradiating a target of an eye is for reducing hyperpermeability of large choroidal vessels in an eye or increasing collagen deposition associated with large choroidal vessels in an eye, or both.
3. The RBS of claim 1 or 2, wherein the method of irradiating a target of an eye is for treating, ameliorating, or managing macular edema, diabetic retinopathy, diabetic macular edema, cystoid macular edema, macular edema secondary to central retinal vein occlusion, or macular edema secondary to branch retinal vein occlusion.
4. The RBS according to any of claims 1-3, wherein the dose is fractionated over a number of sessions.
5. The RBS according to any of claims 1-4, wherein the dose is fractionated over at least 2 sessions.
6. The RBS according to any of claims 1-5, wherein the dose is delivered to the target in a dwell time.
7. The RBS according to any of claims 1-6, wherein the dwell time is from 5 seconds to 2 minutes.
8. The RBS according to any of claims 1-6, wherein the dwell time is from 5 seconds to 10 minutes.
9. The RBS according to any of claims 1-8, wherein the RBS is a source of ionizing radiation.
10. The RBS according to any of claims 1-8, where the RBS is a source of beta radiation.
11. The RBS according to any of claims 1-8, wherein the RBS is a source of X-ray radiation.
12. The RBS according to any of claims 1-11, wherein the cannula is part of a delivery device, wherein the delivery device comprises: a cannula (100) comprising a curved distal portion (110) adapted for placement around a portion of a globe of an eye; a curved proximal portion (120) , the curved distal portion and the curved proximal portions being connected with each other at an inflection point (130) where the direction of the curvature changes sign; and a straight proximal portion, wherein
(a) the distal portion has a radius of curvature (180) between about 9 mm to 15 mm and an arc length between about 25 mm to 35 mm; and
(b) the proximal portion has a radius of curvature (190) between about an inner cross-sectional radius of the cannula and about 1 meter; and wherein an angle Qi (425) between a line ? 3 (420) tangent to the distal portion and to the curved proximal portion at the
inflection point and the straight proximal portion is between greater than about 0 degrees to about 180 degrees.
13. A method of reducing hyperpermeability of large choroidal vessels in an eye of a patient in need thereof with at least one condition selected from the following: macular edema, diabetic retinopathy, diabetic macular edema, cystoid macular edema, macular edema secondary to central retinal vein occlusion, or macular edema secondary to branch retinal vein occlusion, said method comprising inserting a cannula into a potential space under a Tenon' s capsule of the eye of the patient, the cannula having a radionuclide brachytherapy source (RBS) at a treatment position, whereby the RBS is positioned over a target, and wherein a therapeutic dose of radiation is delivered to the target.
14. A method of increasing collagen deposition associated with large choroidal vessels in an eye of a patient in need thereof with at least one condition selected from the following: macular edema, diabetic retinopathy, diabetic macular edema, cystoid macular edema, macular edema secondary to central retinal vein occlusion, or macular edema secondary to branch retinal vein occlusion, said method comprising inserting a cannula into a potential space under a Tenon' s capsule of the eye of the patient, the cannula having a radionuclide brachytherapy source (RBS) at a treatment position, whereby the RBS is positioned over a target, and wherein a therapeutic dose of radiation is delivered to the target.
15. A method of treating at least one condition selected from the following: macular edema, diabetic retinopathy, diabetic macular edema, cystoid macular edema, macular edema
secondary to central retinal vein occlusion, or macular edema secondary to branch retinal vein occlusion in a patient in need thereof, said method comprising inserting a cannula into a potential space under a Tenon' s capsule of an eye of the patient, the cannula having a radionuclide brachytherapy source (RBS) at a treatment position, whereby the RBS is positioned over a target, and wherein a therapeutic dose of radiation is delivered to the target.
16. The method according to any of claims 13-15, wherein the dose is fractionated over a number of sessions.
17. The method according to any of claims 13-15, wherein the dose is fractionated over at least 2 sessions.
18. The method according to any of claims 13-17, wherein the dose is delivered to the target in a dwell time.
19. The method of claim 18, wherein the dwell time is from 5 seconds to 2 minutes.
20. The method of claim 18, wherein the dwell time is from
5 second to 10 minutes.
21. The method according to any of claims 13-20, wherein the RBS is a source of ionizing radiation.
22. The method according to any of claims 13-20, where the RBS is a source of beta radiation.
23. The method according to any of claims 13-20, wherein the RBS is a source of X-ray radiation.
24. The method according to any of claims 13-23, wherein the cannula is part of a delivery device, and wherein the delivery device comprises: a cannula (100) comprising a curved distal portion (110) adapted for placement around a portion of a globe of an eye; a curved proximal portion (120) , the curved distal portion and the curved proximal portions being connected with each other at an inflection point (130) where the direction of the curvature changes sign; and a straight proximal portion, wherein
(a) the distal portion has a radius of curvature (180) between about 9 mm to 15 mm and an arc length between about 25 mm to 35 mm; and
(b) the proximal portion has a radius of curvature (190) between about an inner cross-sectional radius of the cannula and about 1 meter; and wherein an angle Qi (425) between a line ? 3 (420) tangent to the distal portion and to the curved proximal portion at the inflection point and the straight proximal portion is between greater than about 0 degrees to about 180 degrees.
25. The method according to any of claims 13-24, wherein the dose delivered is such that radiation retinopathy is avoided .
26. The method according to any of claims 13-24, wherein the dose delivered is such that radiation choroidopathy is avoided .
27. The method according to any of claims 13-24, wherein the dose delivered is such that radiation maculopathy is avoided .
28. The method according to any of claims 13-24, wherein the dose delivered is such that radiation neuropathy is avoided.
29. The method according to any of claims 13-24, wherein the dose delivered is such that cataract is avoided.
30. The method according to any of claims 13-24, wherein the dose delivered is such that choroidal neovascularization is avoided .
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263381454P | 2022-10-28 | 2022-10-28 | |
US63/381,454 | 2022-10-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024091586A1 true WO2024091586A1 (en) | 2024-05-02 |
Family
ID=90831644
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2023/035967 WO2024091586A1 (en) | 2022-10-28 | 2023-10-26 | Radionuclide brachytherapy source systems for ocular radiotherapy |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024091586A1 (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6413245B1 (en) * | 1999-10-21 | 2002-07-02 | Alcon Universal Ltd. | Sub-tenon drug delivery |
US20040138515A1 (en) * | 2003-01-15 | 2004-07-15 | Jack White | Brachytherapy devices and methods of using them |
WO2007059208A2 (en) * | 2005-11-15 | 2007-05-24 | Neovista Inc. | Methods and apparatus for intraocular brachytherapy |
US20100004499A1 (en) * | 2008-01-07 | 2010-01-07 | Salutarismd | Methods And Devices For Minimally-Invasive Extraocular Delivery of Radiation To The Posterior Portion Of The Eye |
US10850118B2 (en) * | 2008-01-07 | 2020-12-01 | Salutaris Medical Devices, Inc. | Methods and devices for minim ally-invasive delivery of radiation to the eye |
-
2023
- 2023-10-26 WO PCT/US2023/035967 patent/WO2024091586A1/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6413245B1 (en) * | 1999-10-21 | 2002-07-02 | Alcon Universal Ltd. | Sub-tenon drug delivery |
US20040138515A1 (en) * | 2003-01-15 | 2004-07-15 | Jack White | Brachytherapy devices and methods of using them |
WO2007059208A2 (en) * | 2005-11-15 | 2007-05-24 | Neovista Inc. | Methods and apparatus for intraocular brachytherapy |
US20100004499A1 (en) * | 2008-01-07 | 2010-01-07 | Salutarismd | Methods And Devices For Minimally-Invasive Extraocular Delivery of Radiation To The Posterior Portion Of The Eye |
US10850118B2 (en) * | 2008-01-07 | 2020-12-01 | Salutaris Medical Devices, Inc. | Methods and devices for minim ally-invasive delivery of radiation to the eye |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Van Rijssen et al. | Central serous chorioretinopathy: towards an evidence-based treatment guideline | |
Gündüz | Transpupillary thermotherapy in the management of circumscribed choroidal hemangioma | |
Tsipursky et al. | Photodynamic therapy of choroidal hemangioma in sturge-weber syndrome, with a review of treatments for diffuse and circumscribed choroidal hemangiomas | |
Lopez et al. | Bone marrow transplant retinopathy | |
US8602959B1 (en) | Methods and devices for delivery of radiation to the posterior portion of the eye | |
Seregard et al. | Radiation therapy: posterior segment complications | |
Pacella et al. | Testing the effectiveness of intravitreal ranibizumab during 12 months of follow-up in venous occlusion treatment | |
Di Nicola et al. | Photodynamic therapy for retinal hemangioblastoma: treatment outcomes of 17 consecutive patients | |
Parrozzani et al. | Intravitreal triamcinolone versus intravitreal bevacizumab in the treatment of exudative retinal detachment secondary to posterior uveal melanoma | |
Ozdek et al. | Posterior subtenon triamcinolone, intravitreal triamcinolone and grid laser photocoagulation for the treatment of macular edema in branch retinal vein occlusion | |
JP2020055862A (en) | Methods for treating ocular conditions with sustained drug delivery implants | |
Eskelin et al. | Photodynamic therapy with verteporfin to induce regression of aggressive retinal astrocytomas | |
Mennel et al. | Ocular Photodynamic Therapy–Standard Applications and New Indications (Part 2) Review of the Literature and Personal Experience | |
WO2024091586A1 (en) | Radionuclide brachytherapy source systems for ocular radiotherapy | |
WO2023077074A1 (en) | Radionuclide brachytherapy source systems for ocular radiotherapy of chronic serous chorioretinopathy | |
Abolfathzadeh et al. | Ru-106 plaque radiotherapy for vasoproliferative tumors of retina: a 15-year single-center experience | |
Patelli et al. | Optical coherence tomography evaluation of macular edema after radial optic neurotomy in patients affected by central retinal vein occlusion | |
Park et al. | Photodynamic therapy with verteporfin for juxtafoveal choroidal neovascularization in serpiginous choroiditis | |
Ganesan et al. | Surgical implications in exudative retinal detachment | |
Veritti et al. | Triple therapy for anti-vascular endothelial growth factor nonresponders in neovascular age-related macular degeneration: impact of different photodynamic therapy parameters | |
Soucek et al. | Evaluation of subretinal fluid absorption by optical coherence tomography in circumscribed choroidal hemangioma after photodynamic therapy with Verteporfin | |
Suzuki et al. | Vitrectomy for tractional retinal detachment with twin retinal capillary hemangiomas in a patient with Von Hippel-Lindau disease: a case report | |
JP2007500250A (en) | Nonsteroidal anti-inflammatory drug formulations for treating pathological ocular angiogenesis | |
Singh et al. | Expanded indications of plaque brachytherapy | |
JP2007500250A5 (en) |